BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Park K, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, Kölbeck K, Laurie SA, Tsai CM, Shahidi M, Kim M, Massey D, Zazulina V, Paz-Ares L. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol 2016;17:577-89. [PMID: 27083334 DOI: 10.1016/S1470-2045(16)30033-X] [Cited by in Crossref: 529] [Cited by in F6Publishing: 315] [Article Influence: 88.2] [Reference Citation Analysis]
Number Citing Articles
1 Rodríguez-Abreu D, Cobo M, García-Román S, Viteri-Ramírez S, Jordana-Ariza N, García-Peláez B, Reguart N, Aguilar A, Codony-Servat J, Drozdowskyj A, Molina-Vila MA, d'Hondt E, Rosell R. The EPICAL trial, a phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLC. Lung Cancer 2021;164:8-13. [PMID: 34971901 DOI: 10.1016/j.lungcan.2021.12.014] [Reference Citation Analysis]
2 Fenchel K, Dale SP, Dempke WC. Improved overall survival following tyrosine kinase inhibitor (TKI) treatment in NSCLC-are we making progress? Transl Lung Cancer Res 2016;5:373-6. [PMID: 27652201 DOI: 10.21037/tlcr.2016.07.01] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
3 Neal JW, Costa DB, Muzikansky A, Shrager JB, Lanuti M, Huang J, Ramachandran KJ, Rangachari D, Huberman MS, Piotrowska Z, Kris MG, Azzoli CG, Sequist LV, Chaft JE. Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III EGFR-Mutant Non-Small-Cell Lung Cancer. JCO Precis Oncol 2021;5:325-32. [PMID: 34151132 DOI: 10.1200/PO.20.00301] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Liu Q, Luo X, Peng L, Yi L, Wan X, Zeng X, Tan C. Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China. BMJ Open 2020;10:e040691. [PMID: 33243806 DOI: 10.1136/bmjopen-2020-040691] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Buonerba C, Iaccarino S, Dolce P, Pagliuca M, Izzo M, Scafuri L, Costabile F, Riccio V, Ribera D, Mucci B, Carrano S, Picozzi F, Bosso D, Formisano L, Bianco R, De Placido S, Di Lorenzo G. Predictors of Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Receiving EGFR Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis. Cancers (Basel) 2019;11:E1259. [PMID: 31466227 DOI: 10.3390/cancers11091259] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
6 Lu S, Shih JY, Jang TW, Liam CK, Yu Y. Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence. Adv Ther 2021;38:2038-53. [PMID: 33730350 DOI: 10.1007/s12325-021-01696-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
7 Cao F, Xiao Z, Chen S, Zhao C, Chen D, Haisma HJ, Dekker FJ. HDAC/MIF dual inhibitor inhibits NSCLC cell survival and proliferation by blocking the AKT pathway. Bioorg Chem 2021;117:105396. [PMID: 34649152 DOI: 10.1016/j.bioorg.2021.105396] [Reference Citation Analysis]
8 Carmichael JA, Wing-San Mak D, O'Brien M. A Review of Recent Advances in the Treatment of Elderly and Poor Performance NSCLC. Cancers (Basel) 2018;10:E236. [PMID: 30021993 DOI: 10.3390/cancers10070236] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
9 Melosky B, Banerji S, Blais N, Chu Q, Juergens R, Leighl NB, Liu G, Cheema P. Canadian consensus: a new systemic treatment algorithm for advanced EGFR-mutated non-small-cell lung cancer. Curr Oncol 2020;27:e146-55. [PMID: 32489263 DOI: 10.3747/co.27.6007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
10 McGranahan T, Nagpal S. A Neuro-oncologist's Perspective on Management of Brain Metastases in Patients with EGFR Mutant Non-small Cell Lung Cancer. Curr Treat Options Oncol 2017;18:22. [PMID: 28391420 DOI: 10.1007/s11864-017-0466-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
11 Nishiya N, Murai M, Hosoda A, Yonezawa H, Omori N. Bucillamine Prevents Afatinib-Mediated Inhibition of Epidermal Growth Factor Receptor Signaling. Pharmaceuticals (Basel) 2019;12:E165. [PMID: 31703435 DOI: 10.3390/ph12040165] [Reference Citation Analysis]
12 Schuler M, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, Kölbeck K, Massey D, Märten A, Paz-Ares L, Park K. First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression. J Cancer Res Clin Oncol 2019;145:1569-79. [PMID: 30783814 DOI: 10.1007/s00432-019-02862-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
13 Tsukita Y, Inoue A. First-line therapy in non-small cell lung cancer patients with EGFR activating mutations: a consideration of the clinical position of osimertinib based on the subset of Japanese patients in the FLAURA study. Jpn J Clin Oncol 2022:hyac012. [PMID: 35446957 DOI: 10.1093/jjco/hyac012] [Reference Citation Analysis]
14 Yoon S, Lee DH, Kim SW. Gefitinib with pemetrexed as first-line therapy in patients with advanced nonsquamous non-small cell lung cancer with activating epidermal growth factor receptor mutations. Ann Transl Med 2017;5:11. [PMID: 28164096 DOI: 10.21037/atm.2016.12.64] [Reference Citation Analysis]
15 Gridelli C, Losanno T. A potential new therapeutic option for patients with advanced EGFR mutation-positive non-small cell lung cancer in first-line setting. J Thorac Dis 2016;8:E1520-4. [PMID: 28066649 DOI: 10.21037/jtd.2016.11.91] [Reference Citation Analysis]
16 Liang SK, Keng LT, Chang CH, Wen YF, Lee MR, Yang CY, Wang JY, Ko JC, Shih JY, Yu CJ. Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort. Front Oncol 2020;10:590356. [PMID: 33489886 DOI: 10.3389/fonc.2020.590356] [Reference Citation Analysis]
17 Wang M, Zhang Z, Liu J, Song M, Zhang T, Chen Y, Hu H, Yang P, Li B, Song X, Pang J, Xing Y, Cao Z, Guo W, Yang H, Wang J, Yang J, Wang C. Gefitinib and fostamatinib target EGFR and SYK to attenuate silicosis: a multi-omics study with drug exploration. Signal Transduct Target Ther 2022;7:157. [PMID: 35551173 DOI: 10.1038/s41392-022-00959-3] [Reference Citation Analysis]
18 Prabhash K. Treatment of advanced nonsmall cell lung cancer: First line, maintenance and second line - Indian consensus statement update. South Asian J Cancer 2019;8:1-17. [PMID: 30766843 DOI: 10.4103/sajc.sajc_227_18] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
19 Sinkala M, Mulder N, Patrick Martin D. Metabolic gene alterations impact the clinical aggressiveness and drug responses of 32 human cancers. Commun Biol 2019;2:414. [PMID: 31754644 DOI: 10.1038/s42003-019-0666-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
20 Pasello G, Vicario G, Zustovich F, Oniga F, Gori S, Rosetti F, Bonetti A, Favaretto A, Toso S, Redelotti R, Santo A, Bernardi D, Giovanis P, Oliani C, Calvetti L, Gatti C, Palazzolo G, Baretta Z, Bortolami A, Bonanno L, Basso M, Menis J, Corte DD, Frega S, Guarneri V, Conte P; Veneto Oncology Network. From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for EGFR-Positive Non-Small Cell Lung Cancer (MOST Study). Oncologist 2019;24:e318-26. [PMID: 30846513 DOI: 10.1634/theoncologist.2018-0712] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
21 Spicer J, Irshad S, Ang JE, Enting D, Kristeleit R, Uttenreuther-Fischer M, Pemberton K, Pelling K, Schnell D, de Bono J. A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors. Cancer Chemother Pharmacol 2017;79:17-27. [PMID: 27872953 DOI: 10.1007/s00280-016-3189-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
22 Corre R, Gervais R, Guisier F, Tassy L, Vinas F, Lamy R, Fraboulet G, Greillier L, Doubre H, Descourt R, Chouaid C, Auliac JB. Octogenarians with EGFR-mutated non-small cell lung cancer treated by tyrosine-kinase inhibitor: a multicentric real-world study assessing tolerance and efficacy (OCTOMUT study). Oncotarget 2018;9:8253-62. [PMID: 29492192 DOI: 10.18632/oncotarget.23836] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
23 Zheng Q, Huang Y, Zhao H, Yang Y, Hong S, Hou X, Zhao Y, Ma Y, Zhou T, Zhang Y, Fang W, Zhang L. EGFR mutation genotypes affect efficacy and resistance mechanisms of osimertinib in T790M-positive NSCLC patients. Transl Lung Cancer Res 2020;9:471-83. [PMID: 32676311 DOI: 10.21037/tlcr.2020.03.35] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Paz-Ares L, Tan EH, O'Byrne K, Zhang L, Hirsh V, Boyer M, Yang JC, Mok T, Lee KH, Lu S, Shi Y, Lee DH, Laskin J, Kim DW, Laurie SA, Kölbeck K, Fan J, Dodd N, Märten A, Park K. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Ann Oncol 2017;28:270-7. [PMID: 28426106 DOI: 10.1093/annonc/mdw611] [Cited by in Crossref: 230] [Cited by in F6Publishing: 237] [Article Influence: 46.0] [Reference Citation Analysis]
25 Kulkarni AA, Fujioka N, Reinhardt L, Patel MR, Kratzke RA. Exceptional response to afatinib in a patient with persistent G719A EGFR-mutant NSCLC. Lung Cancer Manag 2022;11:LMT54. [PMID: 35463918 DOI: 10.2217/lmt-2021-0001] [Reference Citation Analysis]
26 Garinet S, Laurent-Puig P, Blons H, Oudart JB. Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies? J Clin Med. 2018;7. [PMID: 29890761 DOI: 10.3390/jcm7060144] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 8.0] [Reference Citation Analysis]
27 Hirsh V, Singh J. Optimal sequencing strategies in the treatment of EGFR mutation-positive non-small cell lung cancer: Clinical benefits and cost-effectiveness. Am J Health Syst Pharm 2020;77:1466-76. [PMID: 32885829 DOI: 10.1093/ajhp/zxaa197] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Patil VM, Noronha V, Joshi A, Choughule AB, Bhattacharjee A, Kumar R, Goud S, More S, Ramaswamy A, Karpe A, Pande N, Chandrasekharan A, Goel A, Talreja V, Mahajan A, Janu A, Purandare N, Prabhash K. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma. ESMO Open 2017;2:e000168. [PMID: 28761735 DOI: 10.1136/esmoopen-2017-000168] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
29 Esfahani SA, Callahan C, Rotile NJ, Heidari P, Mahmood U, Caravan PD, Grant AK, Yen YF. Hyperpolarized [1-13C]Pyruvate Magnetic Resonance Spectroscopic Imaging for Evaluation of Early Response to Tyrosine Kinase Inhibition Therapy in Gastric Cancer. Mol Imaging Biol 2022. [PMID: 35467249 DOI: 10.1007/s11307-022-01727-z] [Reference Citation Analysis]
30 Xu J, Zhang X, Yang H, Ding G, Jin B, Lou Y, Zhang Y, Wang H, Han B. Comparison of outcomes of tyrosine kinase inhibitor in first- or second-line therapy for advanced non-small-cell lung cancer patients with sensitive EGFR mutations. Oncotarget 2016;7:68442-8. [PMID: 27637087 DOI: 10.18632/oncotarget.12035] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
31 Su PL, Chen CW, Wu YL, Lin CC, Su WC. First-line treatment with irreversible tyrosine kinase inhibitors associated with longer OS in EGFR mutation-positive non-small cell lung cancer. Thorac Cancer 2021;12:287-96. [PMID: 33336895 DOI: 10.1111/1759-7714.13462] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Sooman L, Gullbo J, Bergqvist M, Bergström S, Lennartsson J, Ekman S. Synergistic effects of combining proteasome inhibitors with chemotherapeutic drugs in lung cancer cells. BMC Res Notes 2017;10:544. [PMID: 29096687 DOI: 10.1186/s13104-017-2842-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
33 Leonetti A, Facchinetti F, Tiseo M. Upfront osimertinib in EGFR-mutated non-small cell lung cancer: is brain still a sanctuary? Ann Transl Med 2018;6:S110. [PMID: 30740431 DOI: 10.21037/atm.2018.11.69] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
34 Lee J, Chen R, Mohanakumar T, Bremner R, Mittal S, Fleming TP. Identification of Phospho-Tyrosine Targets as a Strategy for the Treatment of Esophageal Adenocarcinoma Cells. Onco Targets Ther 2021;14:3813-20. [PMID: 34188489 DOI: 10.2147/OTT.S309388] [Reference Citation Analysis]
35 Oya Y, Yoshida T, Asada K, Oguri T, Inui N, Morikawa S, Ito K, Kimura T, Kunii E, Matsui T, Kubo A, Kato T, Abe T, Tsuda T, Hida T. Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib. BMC Cancer 2021;21:57. [PMID: 33435905 DOI: 10.1186/s12885-020-07777-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Rossi G, Jocollé G, Conti A, Tiseo M, Zito Marino F, Donati G, Franco R, Bono F, Barbisan F, Facchinetti F. Detection of ROS1 rearrangement in non-small cell lung cancer: current and future perspectives. Lung Cancer (Auckl) 2017;8:45-55. [PMID: 28740441 DOI: 10.2147/LCTT.S120172] [Cited by in Crossref: 6] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
37 Khaddour K, Jonna S, Deneka A, Patel JD, Abazeed ME, Golemis E, Borghaei H, Boumber Y. Targeting the Epidermal Growth Factor Receptor in EGFR-Mutated Lung Cancer: Current and Emerging Therapies. Cancers (Basel) 2021;13:3164. [PMID: 34202748 DOI: 10.3390/cancers13133164] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
38 Hayashi H, Nadal E, Gray JE, Ardizzoni A, Caria N, Puri T, Grohe C. Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations. Clin Lung Cancer 2021:S1525-7304(21)00273-4. [PMID: 34865963 DOI: 10.1016/j.cllc.2021.10.009] [Reference Citation Analysis]
39 Reungwetwattana T, Rohatgi N, Mok TS, Prabhash K. Dacomitinib as first-line treatment for EGFR mutation-positive non-small cell lung cancer. Expert Review of Precision Medicine and Drug Development 2021;6:161-71. [DOI: 10.1080/23808993.2021.1909420] [Reference Citation Analysis]
40 Akamatsu H, Ninomiya K, Kenmotsu H, Morise M, Daga H, Goto Y, Kozuki T, Miura S, Sasaki T, Tamiya A, Teraoka S, Tsubata Y, Yoshioka H, Hattori Y, Imamura CK, Katsuya Y, Matsui R, Minegishi Y, Mizugaki H, Nosaki K, Okuma Y, Sakamoto S, Sone T, Tanaka K, Umemura S, Yamanaka T, Amano S, Hasegawa K, Morita S, Nakajima K, Maemondo M, Seto T, Yamamoto N. The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV. Int J Clin Oncol 2019;24:731-70. [PMID: 31049758 DOI: 10.1007/s10147-019-01431-z] [Cited by in Crossref: 33] [Cited by in F6Publishing: 40] [Article Influence: 11.0] [Reference Citation Analysis]
41 Pakkala S, Ramalingam SS. Personalized therapy for lung cancer: striking a moving target. JCI Insight 2018;3:120858. [PMID: 30089719 DOI: 10.1172/jci.insight.120858] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 12.8] [Reference Citation Analysis]
42 Gelatti ACZ, Drilon A, Santini FC. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Lung Cancer. 2019;137:113-122. [PMID: 31568888 DOI: 10.1016/j.lungcan.2019.09.017] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 13.3] [Reference Citation Analysis]
43 Zou B, Lee VHF, Chen L, Ma L, Wang DD, Yan H. Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations. Sci Rep 2017;7:6595. [PMID: 28747773 DOI: 10.1038/s41598-017-06632-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
44 Hayashi H, Yonesaka K, Nakamura A, Fujimoto D, Azuma K, Sakata S, Tachihara M, Ikeda S, Yokoyama T, Hataji O, Yano Y, Hirano K, Daga H, Okada H, Chiba Y, Sakai K, Nishio K, Yamamoto N, Nakagawa K. Alternating Therapy with Osimertinib and Afatinib for Treatment-Naive Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer: A Single-Group, Open-Label Phase 2 Trial (WJOG10818L). Lung Cancer 2022. [DOI: 10.1016/j.lungcan.2022.04.004] [Reference Citation Analysis]
45 Popat S, Jung HA, Lee SY, Hochmair MJ, Lee SH, Escriu C, Lee MK, Migliorino MR, Lee YC, Girard N, Daoud H, Märten A, Miura S. Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG). Lung Cancer 2021;162:9-15. [PMID: 34649106 DOI: 10.1016/j.lungcan.2021.09.009] [Reference Citation Analysis]
46 Takeda M, Nakagawa K. First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer? Int J Mol Sci 2019;20:E146. [PMID: 30609789 DOI: 10.3390/ijms20010146] [Cited by in Crossref: 58] [Cited by in F6Publishing: 45] [Article Influence: 19.3] [Reference Citation Analysis]
47 Zhang L, Chen B, Liu X, Song J, Fang M, Hu C, Dong D, Li W, Tian J. Quantitative Biomarkers for Prediction of Epidermal Growth Factor Receptor Mutation in Non-Small Cell Lung Cancer. Transl Oncol 2018;11:94-101. [PMID: 29216508 DOI: 10.1016/j.tranon.2017.10.012] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 8.4] [Reference Citation Analysis]
48 Kawana S, Saito R, Miki Y, Kimura Y, Abe J, Sato I, Endo M, Sugawara S, Sasano H. Suppression of tumor immune microenvironment via microRNA-1 after epidermal growth factor receptor-tyrosine kinase inhibitor resistance acquirement in lung adenocarcinoma. Cancer Med 2021;10:718-27. [PMID: 33305905 DOI: 10.1002/cam4.3639] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
49 Cheema PK, Gomes M, Banerji S, Joubert P, Leighl NB, Melosky B, Sheffield BS, Stockley T, Ionescu DN. Consensus recommendations for optimizing biomarker testing to identify and treat advanced EGFR-mutated non-small-cell lung cancer. Curr Oncol 2020;27:321-9. [PMID: 33380864 DOI: 10.3747/co.27.7297] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
50 Hirsh V. Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors. Ther Adv Med Oncol 2018;10:1758834017753338. [PMID: 29383041 DOI: 10.1177/1758834017753338] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 8.3] [Reference Citation Analysis]
51 Rybarczyk-Kasiuchnicz A, Ramlau R, Stencel K. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma. Int J Mol Sci 2021;22:E593. [PMID: 33435596 DOI: 10.3390/ijms22020593] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
52 Hopkins AM, Nguyen AM, Karapetis CS, Rowland A, Sorich MJ. Risk Factors for Severe Diarrhea with an Afatinib Treatment of Non-Small Cell Lung Cancer: A Pooled Analysis of Clinical Trials. Cancers (Basel) 2018;10:E384. [PMID: 30326638 DOI: 10.3390/cancers10100384] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
53 Bayazeid O, Rahman T. Correlation Analysis of Target Selectivity and Side Effects of FDA‐Approved Kinase Inhibitors**. ChemistrySelect 2021;6:7799-814. [DOI: 10.1002/slct.202101367] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Yu B, Zheng L, Tang H, Wang W, Lin Y. Cucurbitacin B enhances apoptosis in gefitinib resistant non‑small cell lung cancer by modulating the miR‑17‑5p/STAT3 axis. Mol Med Rep 2021;24:710. [PMID: 34396444 DOI: 10.3892/mmr.2021.12349] [Reference Citation Analysis]
55 Jung HA, Woo SY, Lee SH, Ahn JS, Ahn MJ, Park K, Sun JM. The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer. Transl Lung Cancer Res 2020;9:1749-58. [PMID: 33209598 DOI: 10.21037/tlcr-20-379] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
56 Le T, Gerber DE. Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used? Cancers (Basel). 2019;11. [PMID: 30875928 DOI: 10.3390/cancers11030366] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 8.0] [Reference Citation Analysis]
57 Pompilio G, Morabito A, Cortinovis DL, Integlia D. Budget Impact Analysis of afatinib for first-line treatment of Non-Small Cell Lung Cancer (NSCLC) patients with uncommon EGFR mutations. Grhta 2022;9:22-9. [DOI: 10.33393/grhta.2022.2351] [Reference Citation Analysis]
58 Lee CS, Sharma S, Miao E, Mensah C, Sullivan K, Seetharamu N. A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity. Lung Cancer (Auckl) 2020;11:73-103. [PMID: 33117017 DOI: 10.2147/LCTT.S258444] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
59 Taniguchi Y, Tamiya A, Nakahama K, Naoki Y, Kanazu M, Omachi N, Okishio K, Kasai T, Atagi S. Impact of metastatic status on the prognosis of EGFR mutation-positive non-small cell lung cancer patients treated with first-generation EGFR-tyrosine kinase inhibitors. Oncol Lett 2017;14:7589-96. [PMID: 29344206 DOI: 10.3892/ol.2017.7125] [Cited by in Crossref: 3] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
60 Lin A, Wei T, Meng H, Luo P, Zhang J. Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations. Mol Cancer 2019;18:139. [PMID: 31526368 DOI: 10.1186/s12943-019-1062-7] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 14.7] [Reference Citation Analysis]
61 Wang S, Xing P, Yang K, Hao X, Ma D, Mu Y, Li J. Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations. Thorac Cancer 2019;10:1461-8. [PMID: 31095895 DOI: 10.1111/1759-7714.13095] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
62 Abdallah SM, Hirsh V. Irreversible tyrosine kinase inhibition of epidermal growth factor receptor with afatinib in EGFR activating mutation-positive advanced non-small-cell lung cancer. Curr Oncol 2018;25:S9-S17. [PMID: 29910643 DOI: 10.3747/co.25.3732] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
63 Guan S, Chen X, Xin S, Liu S, Yang Y, Fang W, Huang Y, Zhao H, Zhu X, Zhuang W, Wang F, Feng W, Zhang X, Huang M, Wang X, Zhang L. Establishment and application of a predictive model for gefitinib-induced severe rash based on pharmacometabolomic profiling and polymorphisms of transporters in non-small cell lung cancer. Transl Oncol 2021;14:100951. [PMID: 33221684 DOI: 10.1016/j.tranon.2020.100951] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
64 Isla D, De Castro J, Juan O, Grau S, Orofino J, Gordo R, Rubio-Terrés C, Rubio-Rodríguez D. Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer. Clinicoecon Outcomes Res 2017;9:31-8. [PMID: 28115857 DOI: 10.2147/CEOR.S121093] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 2.2] [Reference Citation Analysis]
65 Wu YL, Xu CR, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Märten A, Fan J, Peil B, Zhou C. Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial. Onco Targets Ther 2018;11:8575-87. [PMID: 30584317 DOI: 10.2147/OTT.S160358] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
66 Tan CS, Kumarakulasinghe NB, Huang YQ, Ang YLE, Choo JR, Goh BC, Soo RA. Third generation EGFR TKIs: current data and future directions. Mol Cancer 2018;17:29. [PMID: 29455654 DOI: 10.1186/s12943-018-0778-0] [Cited by in Crossref: 86] [Cited by in F6Publishing: 80] [Article Influence: 21.5] [Reference Citation Analysis]
67 Wang X, Goldstein D, Crowe PJ, Yang JL. Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence. Onco Targets Ther 2016;9:5461-73. [PMID: 27660463 DOI: 10.2147/OTT.S94745] [Cited by in Crossref: 30] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
68 Juan O, Popat S. Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications. Ther Adv Med Oncol 2017;9:201-16. [PMID: 28344665 DOI: 10.1177/1758834016687262] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
69 Chen R, Xu X, Qian Z, Zhang C, Niu Y, Wang Z, Sun J, Zhang X, Yu Y. The biological functions and clinical applications of exosomes in lung cancer. Cell Mol Life Sci 2019;76:4613-33. [DOI: 10.1007/s00018-019-03233-y] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 10.3] [Reference Citation Analysis]
70 O'Kane GM, Su J, Tse BC, Tam V, Tse T, Lu L, Borean M, Tam E, Labbé C, Naik H, Mittmann N, Doherty MK, Bradbury PA, Leighl NB, Shepherd FA, Richard NM, Edelstein K, Shultz D, Brown MC, Xu W, Howell D, Liu G. The Impact of Brain Metastases and Associated Neurocognitive Aspects on Health Utility Scores in EGFR Mutated and ALK Rearranged NSCLC: A Real World Evidence Analysis. Oncologist 2019;24:e501-9. [PMID: 30952820 DOI: 10.1634/theoncologist.2018-0544] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
71 Karachaliou N, Chaib I, Cardona AF, Berenguer J, Bracht JWP, Yang J, Cai X, Wang Z, Hu C, Drozdowskyj A, Servat CC, Servat JC, Ito M, Attili I, Aldeguer E, Capitan AG, Rodriguez J, Rojas L, Viteri S, Molina-Vila MA, Ou SI, Okada M, Mok TS, Bivona TG, Ono M, Cui J, Ramón Y Cajal S, Frias A, Cao P, Rosell R. Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis. EBioMedicine 2018;29:112-27. [PMID: 29433983 DOI: 10.1016/j.ebiom.2018.02.001] [Cited by in Crossref: 34] [Cited by in F6Publishing: 41] [Article Influence: 8.5] [Reference Citation Analysis]
72 Aktürk C. Bibliometric Analysis of Clinical Decision Support Systems. AIP 2021;10:61-74. [DOI: 10.18267/j.aip.146] [Reference Citation Analysis]
73 Yoon BW, Kim JH, Lee SH, Choi CM, Rho JK, Yoon S, Lee DH, Kim SW, Jang TW, Lee JC. Comparison of T790M Acquisition Between Patients Treated with Afatinib and Gefitinib as First-Line Therapy: Retrospective Propensity Score Matching Analysis. Transl Oncol 2019;12:852-8. [PMID: 31030101 DOI: 10.1016/j.tranon.2019.04.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
74 Wang C, Li Y, Ke L, Cao L, Fan P, Wu Z, Wu Q. The Impact of Afatinib on Survival in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials. J Cancer 2019;10:885-92. [PMID: 30854094 DOI: 10.7150/jca.27528] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
75 Zeng X, Wan X, Xu J, Wang H, Chen H, Zeng Q, Zhang W, Zhao B. Therapeutic options for advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer: a Bayesian network secondary analysis. Aging (Albany NY) 2020;12:7129-62. [PMID: 32324592 DOI: 10.18632/aging.103066] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
76 Wu X, Zhang Y, Li W, Liu T, Yang Y, Wang Y, Zhang Y. A Validated LC Method for the Enantiomeric Separation of EAI045 on Chiral Stationary Phase. J Chromatogr Sci 2020;58:562-8. [PMID: 32303742 DOI: 10.1093/chromsci/bmz125] [Reference Citation Analysis]
77 Lee CS, Milone M, Seetharamu N. Osimertinib in EGFR-Mutated Lung Cancer: A Review of the Existing and Emerging Clinical Data. Onco Targets Ther 2021;14:4579-97. [PMID: 34471361 DOI: 10.2147/OTT.S227032] [Reference Citation Analysis]
78 Chen H, Xu X, Ge T, Hua C, Zhu X, Wang Q, Yu Z, Zhang R. A Novel Tool for the Risk Assessment and Personalized Chemo-/Immunotherapy Response Prediction of Adenocarcinoma and Squamous Cell Carcinoma Lung Cancer. Int J Gen Med 2021;14:5771-85. [PMID: 34557029 DOI: 10.2147/IJGM.S327641] [Reference Citation Analysis]
79 Ng WW, Lin CC, Cheng CY, Jiang JS, Kao SJ, Yeh DY. Real-world outcomes of first- and second-generation tyrosine kinase inhibitors first-line in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer: A retrospective observational cohort study. PLoS One 2021;16:e0253335. [PMID: 34166400 DOI: 10.1371/journal.pone.0253335] [Reference Citation Analysis]
80 Nakao A, Hiranuma O, Uchino J, Sakaguchi C, Araya T, Hiraoka N, Ishizuka T, Takeda T, Kawasaki M, Goto Y, Imai H, Hattori N, Nakatomi K, Uramoto H, Uryu K, Fukuda M, Uchida Y, Yokoyama T, Akai M, Mio T, Nagashima S, Chihara Y, Tamiya N, Kaneko Y, Mouri T, Yamada T, Yoshimura K, Fujita M, Takayama K. Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment. J Clin Med 2020;9:E1762. [PMID: 32517152 DOI: 10.3390/jcm9061762] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
81 Kano H, Ichihara E, Harada D, Inoue K, Kayatani H, Hosokawa S, Kishino D, Watanabe K, Ochi N, Oda N, Hara N, Ninomiya K, Hotta K, Maeda Y, Kiura K. Utility of immune checkpoint inhibitors in non-small-cell lung cancer patients with poor performance status. Cancer Sci 2020;111:3739-46. [PMID: 32726470 DOI: 10.1111/cas.14590] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
82 Sonehara K, Kobayashi T, Tateishi K, Morozumi N, Yoshiike F, Hachiya T, Ono Y, Takasuna K, Agatsuma T, Masubuchi T, Matsuo A, Tanaka H, Morikawa A, Hanaoka M, Koizumi T. Clinical analysis of EGFR-positive non-small cell lung cancer patients treated with first-line afatinib: A Nagano Lung Cancer Research Group. Thorac Cancer 2019;10:1078-85. [PMID: 31006178 DOI: 10.1111/1759-7714.13047] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
83 Kuan FC, Li SH, Wang CL, Lin MH, Tsai YH, Yang CT. Analysis of progression-free survival of first-line tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring leu858Arg or exon 19 deletions. Oncotarget 2017;8:1343-53. [PMID: 27935868 DOI: 10.18632/oncotarget.13815] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
84 Yang Y, Liu Q, Cao L, Sun W, Gu X, Liu B, Xiao N, Teng F, Li X, Chen M, Yu W, Lin H, Xu G. Osimertinib versus afatinib in patients with T790M-positive, non-small-cell lung cancer and multiple central nervous system metastases after failure of initial EGFR-TKI treatment. BMC Pulm Med 2021;21:172. [PMID: 34011336 DOI: 10.1186/s12890-021-01539-x] [Reference Citation Analysis]
85 Sutandyo N, Hanafi A, Jayusman M. [Comparison of Effectiveness of Gefitinib, Erlotinib, and Afatinib in Advanced Non-small Cell Lung Cancer Patients with EGFR Mutation Positive in Indonesian Population]. Zhongguo Fei Ai Za Zhi 2019;22:562-7. [PMID: 31526459 DOI: 10.3779/j.issn.1009-3419.2019.09.02] [Reference Citation Analysis]
86 Fujita K, Morishima Y, Aida Y, Tsunoda Y, Hida N, Shiozawa T, Nakazawa K, Sekine I, Hizawa N. Afatinib-Induced Severe Interstitial Lung Disease Successfully Treated with High-Dose Corticosteroid Therapy: A Case Report. J Thorac Oncol 2017;12:e11-3. [PMID: 27780779 DOI: 10.1016/j.jtho.2016.10.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
87 Hirsh V. New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib. Onco Targets Ther 2017;10:2513-26. [PMID: 28546756 DOI: 10.2147/OTT.S104177] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
88 Nishio M, Kato T, Niho S, Yamamoto N, Takahashi T, Nogami N, Kaneda H, Fujita Y, Wilner K, Yoshida M, Isozaki M, Wada S, Tsuji F, Nakagawa K. Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer. Cancer Sci 2020;111:1724-38. [PMID: 32159882 DOI: 10.1111/cas.14384] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
89 Wang LY, Cui JJ, Guo AX, Yin JY. Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients. Onco Targets Ther 2018;11:529-38. [PMID: 29416353 DOI: 10.2147/OTT.S136579] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
90 Batson S, Mitchell SA, Windisch R, Damonte E, Munk VC, Reguart N. Tyrosine kinase inhibitor combination therapy in first-line treatment of non-small-cell lung cancer: systematic review and network meta-analysis. Onco Targets Ther 2017;10:2473-82. [PMID: 28503070 DOI: 10.2147/OTT.S134382] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 4.4] [Reference Citation Analysis]
91 Yao ZH, Liao WY, Ho CC, Chen KY, Shih JY, Chen JS, Lin ZZ, Lin CC, Chih-Hsin Yang J, Yu CJ. Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib. Oncologist 2017;22:1075-83. [PMID: 28507206 DOI: 10.1634/theoncologist.2016-0331] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
92 Zhang B, Shi C, Gao Z, Zhong H, Xiong L, Gu A, Wang W, Chu T, Zhang W, Wang H, Zhang X, Zhong R, Han B. Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and single arm study (DANCE study). BMC Cancer 2022;22. [DOI: 10.1186/s12885-022-09409-3] [Reference Citation Analysis]
93 Kim Y, Lee SH, Ahn JS, Ahn MJ, Park K, Sun JM. Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib. Cancer Res Treat 2019;51:502-9. [PMID: 29898592 DOI: 10.4143/crt.2018.117] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 6.8] [Reference Citation Analysis]
94 West H. Prioritizing molecular markers to test for in the initial workup of advanced non-small cell lung cancer: wants versus needs. Ann Transl Med 2017;5:371. [PMID: 29057231 DOI: 10.21037/atm.2017.08.29] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
95 Liang SK, Lee MR, Liao WY, Ho CC, Ko JC, Shih JY. Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: a real-world, large cohort study. Oncotarget 2018;9:23749-60. [PMID: 29805772 DOI: 10.18632/oncotarget.25255] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
96 He J, Huang Z, Han L, Gong Y, Xie C. Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer (Review). Int J Oncol 2021;59:90. [PMID: 34558640 DOI: 10.3892/ijo.2021.5270] [Reference Citation Analysis]
97 Li W, Qian L, Li W, Chen X, He H, Tian H, Zhao Y, Wang X, Cui J. Cost-effectiveness analysis of different sequences of osimertinib administration for epidermal growth factor receptor-mutated non-small-cell lung cancer. Exp Ther Med 2021;21:343. [PMID: 33732316 DOI: 10.3892/etm.2021.9774] [Reference Citation Analysis]
98 Wang W, Xia X, Chen K, Chen M, Meng Y, Lv D, Yang H. Reduced PHLPP Expression Leads to EGFR-TKI Resistance in Lung Cancer by Activating PI3K-AKT and MAPK-ERK Dual Signaling. Front Oncol 2021;11:665045. [PMID: 34168988 DOI: 10.3389/fonc.2021.665045] [Reference Citation Analysis]
99 Wang Y, Huang K, Sun S, Deng Y, Xie X. Cost-Effectiveness Analysis of Gefitinib Alone and Combined with Chemotherapy as First-Line Treatment for Patients with Advanced Non-Small-Cell Lung Cancer. Risk Manag Healthc Policy 2022;15:351-9. [PMID: 35256866 DOI: 10.2147/RMHP.S352827] [Reference Citation Analysis]
100 Dempke WCM, Fenchel K. Treating epidermal growth factor receptor-mutated non-small cell lung cancer-is dacomitinib the winner? Transl Lung Cancer Res 2017;6:S88-91. [PMID: 29300395 DOI: 10.21037/tlcr.2017.06.09] [Reference Citation Analysis]
101 Park K, Wan-Teck Lim D, Okamoto I, Yang JC. First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting. Ther Adv Med Oncol 2019;11:1758835919836374. [PMID: 31019567 DOI: 10.1177/1758835919836374] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
102 Liu CY, Wang CL, Li SH, Hsu PC, Chen CH, Lin TY, Kuo CH, Fang YF, Ko HW, Yu CT, Yang TY, Yang CT. The efficacy of 40 mg versus dose de-escalation to less than 40 mg of afatinib (Giotrif) as the first-line therapy for patients with primary lung adenocarcinoma harboring favorable epidermal growth factor mutations. Oncotarget 2017;8:97602-12. [PMID: 29228636 DOI: 10.18632/oncotarget.18746] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
103 Wang P, Li Y, Lv D, Yang L, Ding L, Zhou J, Hong W, Chen Y, Zhang D, He S, Zhou J, Wang K. Mefatinib as first-line treatment of patients with advanced EGFR-mutant non-small-cell lung cancer: a phase Ib/II efficacy and biomarker study. Signal Transduct Target Ther 2021;6:374. [PMID: 34719670 DOI: 10.1038/s41392-021-00773-3] [Reference Citation Analysis]
104 Stock-Martineau S, Shepherd FA. EGFR Tyrosine Kinase Inhibitor Monotherapy Should Remain the Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC. J Thorac Oncol 2021;16:1793-7. [PMID: 34716003 DOI: 10.1016/j.jtho.2021.08.015] [Reference Citation Analysis]
105 Alanazi A, Yunusa I, Elenizi K, Alzarea AI. Efficacy and safety of tyrosine kinase inhibitors in advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutation: a network meta-analysis. Lung Cancer Manag 2020;10:LMT43. [PMID: 33318755 DOI: 10.2217/lmt-2020-0011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
106 Kang HJ, Kim J, Cho SH, Park SJ, Yoo HS, Kang IC. Inhibitory Effects of HangAmDan-B1 (HAD-B1) Combined With Afatinib on H1975 Lung Cancer Cell-Bearing Mice. Integr Cancer Ther 2019;18:1534735419830765. [PMID: 30866688 DOI: 10.1177/1534735419830765] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
107 Bulbul A, Husain H. First-Line Treatment in EGFR Mutant Non-Small Cell Lung Cancer: Is There a Best Option? Front Oncol 2018;8:94. [PMID: 29755953 DOI: 10.3389/fonc.2018.00094] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
108 Holleman MS, Al MJ, Zaim R, Groen HJM, Uyl-de Groot CA. Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations. Eur J Health Econ 2020;21:153-64. [PMID: 31541309 DOI: 10.1007/s10198-019-01117-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
109 Yufen X, Binbin S, Wenyu C, Jialiang L, Xinmei Y. The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer. Springerplus 2016;5:1244. [PMID: 27536527 DOI: 10.1186/s40064-016-2873-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
110 Amiri Souri E, Laddach R, Karagiannis SN, Papageorgiou LG, Tsoka S. Novel drug-target interactions via link prediction and network embedding. BMC Bioinformatics 2022;23:121. [PMID: 35379165 DOI: 10.1186/s12859-022-04650-w] [Reference Citation Analysis]
111 Economopoulou P, Mountzios G. The emerging treatment landscape of advanced non-small cell lung cancer. Ann Transl Med 2018;6:138. [PMID: 29862227 DOI: 10.21037/atm.2017.11.07] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
112 Melosky B. Rapidly changing treatment algorithms for metastatic nonsquamous non-small-cell lung cancer. Curr Oncol 2018;25:S68-76. [PMID: 29910649 DOI: 10.3747/co.25.3839] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
113 Ichiki M, Wataya H, Yamada K, Tsuruta N, Takeoka H, Okayama Y, Sasaki J, Hoshino T. Preventive effect of kampo medicine (hangeshashin-to, TJ-14) plus minocycline against afatinib-induced diarrhea and skin rash in patients with non-small cell lung cancer. Onco Targets Ther 2017;10:5107-13. [PMID: 29123409 DOI: 10.2147/OTT.S145613] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
114 Rybarczyk-Kasiuchnicz A, Ramlau R. Current views on molecularly targeted therapy for lung cancer - a review of literature from the last five years. Kardiochir Torakochirurgia Pol 2018;15:119-24. [PMID: 30069193 DOI: 10.5114/kitp.2018.76478] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
115 Wo H, He J, Zhao Y, Yu H, Chen F, Yi H. The Efficacy and Toxicity of Gefitinib in Treating Non-small Cell Lung Cancer: A Meta-analysis of 19 Randomized Clinical Trials. J Cancer 2018;9:1455-65. [PMID: 29721056 DOI: 10.7150/jca.23356] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
116 Yamamoto Y, Saita T, Oka A, Kataoka H, Shin M. Localization and Accumulation Studies of Dacomitinib in Rat Intestines and Skin by Immunohistochemistry. Acta Histochem Cytochem 2019;52:101-6. [PMID: 32001948 DOI: 10.1267/ahc.19031] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
117 Zhu J, Yang Q, Xu W. Iterative Upgrading of Small Molecular Tyrosine Kinase Inhibitors for EGFR Mutation in NSCLC: Necessity and Perspective. Pharmaceutics 2021;13:1500. [PMID: 34575576 DOI: 10.3390/pharmaceutics13091500] [Reference Citation Analysis]
118 Kobayashi Y, Mitsudomi T. Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy. Cancer Sci 2016;107:1179-86. [PMID: 27323238 DOI: 10.1111/cas.12996] [Cited by in Crossref: 152] [Cited by in F6Publishing: 151] [Article Influence: 25.3] [Reference Citation Analysis]
119 Bylicki O, Paleiron N, Assié JB, Chouaïd C. Targeting the MET-Signaling Pathway in Non-Small-Cell Lung Cancer: Evidence to Date. Onco Targets Ther 2020;13:5691-706. [PMID: 32606781 DOI: 10.2147/OTT.S219959] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
120 Yonesaka K. HER2-/HER3-Targeting Antibody-Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors. Cancers (Basel) 2021;13:1047. [PMID: 33801379 DOI: 10.3390/cancers13051047] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
121 Cheema PK, Thawer A, Leake J, Cheng SY, Khanna S, Charles Victor J. Multi-disciplinary proactive follow-up algorithm for patients with advanced NSCLC receiving afatinib. Support Care Cancer 2019;27:1029-39. [PMID: 30116943 DOI: 10.1007/s00520-018-4392-x] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
122 Ye J, Chen P, Chuang J, Lin M, Tsai T, Hsu H, Chen J. Treatment Effectiveness and Tolerability of Long-term Adjuvant First- and Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor at Different Doses in Patients With Stage IIA–IIIB Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: A Retrospective Study. Front Surg 2022;9:816018. [DOI: 10.3389/fsurg.2022.816018] [Reference Citation Analysis]
123 Romero A, Jantus-Lewintre E, García-Peláez B, Royuela A, Insa A, Cruz P, Collazo A, Pérez Altozano J, Vidal OJ, Diz P, Cobo M, Hernández B, Vázquez Estevez S, Benítez G, Guirado M, Majem M, Bernabé R, Ortega AL, Blasco A, Bosch-Barrera J, Jurado JM, García González J, Viteri S, Garcia Giron C, Massutí B, Lopez Martín A, Rodriguez-Festa A, Calabuig-Fariñas S, Molina-Vila MÁ, Provencio M. Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing: results of the RING observational trial. Mol Oncol 2021;15:43-56. [PMID: 33107189 DOI: 10.1002/1878-0261.12832] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
124 Chang JW, Huang CY, Fang YF, Chang CF, Yang CT, Kuo CS, Hsu PC, Wu CE. Epidermal growth factor receptor tyrosine kinase inhibitors for de novo T790M mutation: A retrospective study of 44 patients. Thorac Cancer 2022. [PMID: 35633141 DOI: 10.1111/1759-7714.14272] [Reference Citation Analysis]
125 Feng Y, Zhu G, Lang S, Hao P, Li G, Chen F, Zhuo W, Duan Y, Zhang A, Chen Z, Sun J. The Efficacy and Safety of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Thymosin in Advanced Non-Small Cell Lung Cancer Patients Harboring Active Epidermal Growth Factor Receptor Mutations. Front Oncol 2021;11:659065. [PMID: 34123814 DOI: 10.3389/fonc.2021.659065] [Reference Citation Analysis]
126 Soulières D, Gelmon KA. Sotorasib: Is Maximum Tolerated Dose Really the Issue at Hand? J Clin Oncol 2021;39:3427-9. [PMID: 34543060 DOI: 10.1200/JCO.21.02072] [Reference Citation Analysis]
127 Kawaguchi Y, Okano T, Imai K, Maehara S, Maeda J, Yoshida K, Hagiwara M, Kakihana M, Kajiwara N, Ohira T, Matsubayashi J, Ikeda N. Epidermal growth factor receptor mutation subtype has differential effects on adjuvant chemotherapy for resected adenocarcinoma pathological stages II-III. Oncol Lett 2019;18:6451-8. [PMID: 31807168 DOI: 10.3892/ol.2019.11050] [Reference Citation Analysis]
128 Ntzifa A, Londra D, Rampias T, Kotsakis A, Georgoulias V, Lianidou E. DNA Methylation Analysis in Plasma Cell-Free DNA and Paired CTCs of NSCLC Patients before and after Osimertinib Treatment. Cancers (Basel) 2021;13:5974. [PMID: 34885084 DOI: 10.3390/cancers13235974] [Reference Citation Analysis]
129 Cadranel J. Osimertinib in first-line treatment-is a comparison not proof? Ann Transl Med 2018;6:57. [PMID: 29611546 DOI: 10.21037/atm.2017.12.13] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
130 Ito K, Murotani K, Kubo A, Kunii E, Taniguchi H, Shindoh J, Asada K, Imaizumi K, Takahashi K, Karayama M, Okuno M, Inui N, Hataji O, Morikawa S, Hayai S, Suda T, Abe T, Tsuda T, Yamagichi T, Kimura T, Oya Y, Yoshida T, Hida T. Propensity score analysis of overall survival between first- and second-generation EGFR-TKIs using real-world data. Cancer Sci 2020;111:3705-13. [PMID: 32639668 DOI: 10.1111/cas.14560] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
131 Giusti R, Mazzotta M, Iacono D, Lauro S, Marchetti P. Complete Tumor Response with Afatinib 20 mg Daily in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report. Clin Drug Investig 2017;37:581-5. [PMID: 28299582 DOI: 10.1007/s40261-017-0515-2] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
132 Liu YT, Zhang K, Li CC, Hu XS, Jiang J, Hao XZ, Wang Y, Li JL, Xing PY, Yang S, Zhang X, Wang GQ, Cai SL, Shi YK. Depth of Response was Associated with Progression-Free Survival in Patients with Advanced Non-small Cell Lung Cancer treated with EGFR-TKI. J Cancer 2019;10:5108-13. [PMID: 31602263 DOI: 10.7150/jca.33450] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
133 Poh ME, Liam CK, Rajadurai P, Chai CS. Epithelial-to-mesenchymal transition (EMT) causing acquired resistance to afatinib in a patient with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma. J Thorac Dis 2018;10:E560-3. [PMID: 30174934 DOI: 10.21037/jtd.2018.06.122] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
134 He SY, Lin QF, Chen J, Yu GP, Zhang JL, Shen D. Efficacy of afatinib in a patient with rare EGFR (G724S/R776H) mutations and amplification in lung adenocarcinoma: A case report. World J Clin Cases 2021; 9(6): 1329-1335 [PMID: 33644199 DOI: 10.12998/wjcc.v9.i6.1329] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
135 Frega S, Lorenzi M, Fassan M, Indraccolo S, Calabrese F, Favaretto A, Bonanno L, Polo V, Zago G, Lunardi F, Attili I, Pavan A, Rugge M, Guarneri V, Conte P, Pasello G. Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations. Oncotarget 2017;8:32626-38. [PMID: 28427238 DOI: 10.18632/oncotarget.15945] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
136 Tanaka K, Nosaki K, Otsubo K, Azuma K, Sakata S, Ouchi H, Morinaga R, Wataya H, Fujii A, Nakagaki N, Tsuruta N, Takeshita M, Iwama E, Harada T, Nakanishi Y, Okamoto I. Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-naïve patients with non-small cell lung cancer harboring EGFR mutations. Oncotarget 2017;8:68123-30. [PMID: 28978102 DOI: 10.18632/oncotarget.19243] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 8.0] [Reference Citation Analysis]
137 Yang SC, Lin CC, Lai WW, Chang SM, Hwang JS, Su WC, Wang JD. Dynamic changes in quality of life after three first-line therapies for EGFR mutation-positive advanced non-small-cell lung cancer. Ther Adv Med Oncol 2018;10:1758834018755072. [PMID: 29434678 DOI: 10.1177/1758834018755072] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
138 Schoenmaekers JJAO, Paats MS, Dingemans AC, Hendriks LEL. Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer: how to treat and when? Transl Lung Cancer Res 2020;9:2599-617. [PMID: 33489821 DOI: 10.21037/tlcr-20-459] [Reference Citation Analysis]
139 Nan X, Xie C, Yu X, Liu J. EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer. Oncotarget 2017;8:75712-26. [PMID: 29088904 DOI: 10.18632/oncotarget.20095] [Cited by in Crossref: 50] [Cited by in F6Publishing: 58] [Article Influence: 10.0] [Reference Citation Analysis]
140 Liu J, Zhang H, Zhu X, Chen H, Li X, Ding Y. Phase I Trial to Evaluate the Tolerance, Pharmacokinetics and Efficacy of the Broad-Spectrum ErbB Family Inhibitor Larotinib Mesylate in Patients With Advanced Solid Tumors. Front Pharmacol 2021;12:636324. [PMID: 33679419 DOI: 10.3389/fphar.2021.636324] [Reference Citation Analysis]
141 Zhao Y, Wang S, Yang Z, Dong Y, Wang Y, Zhang L, Hu H, Han B. Co-Occurring Potentially Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer. Front Oncol 2021;11:665484. [PMID: 34221980 DOI: 10.3389/fonc.2021.665484] [Reference Citation Analysis]
142 Imamura F, Inoue T, Kunimasa K, Kubota A, Kuhara H, Tamiya M, Nishino K, Kimura M, Kuno K, Kawachi H, Kumagai T. Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC. Lung Cancer Manag 2020;9:LMT29. [PMID: 32346403 DOI: 10.2217/lmt-2020-0005] [Reference Citation Analysis]
143 Bai R, Chen X, Song W, Tian H, Cui J. Therapeutic exploration of uncommon EGFR exon 20 insertion mutations in advanced non-small cell lung cancer: breaking through brambles and thorns. J Cancer Res Clin Oncol 2021. [PMID: 34698913 DOI: 10.1007/s00432-021-03840-y] [Reference Citation Analysis]
144 Chitturi KR, Burns EA, Muhsen IN, Anand K, Trachtenberg BH. Cardiovascular Risks with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors and Monoclonal Antibody Therapy. Curr Oncol Rep 2022. [PMID: 35192115 DOI: 10.1007/s11912-022-01215-1] [Reference Citation Analysis]
145 Wu CE, Chang CF, Huang CY, Yang CT, Kuo CS, Hsu PC, Chang JW. Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study. BMC Cancer 2021;21:859. [PMID: 34315431 DOI: 10.1186/s12885-021-08587-w] [Reference Citation Analysis]
146 Bilgin B, Sendur MAN, Yucel S, Celik E, Ozyukseler DT, Ayhan M, Basoglu T, Ilhan A, Akdeniz N, Gulmez A, Dogan I, Aktas BY, Gurbuz M, Koca S, Paydas S, Tatli AM, Cinkir HY, Alan O, Erol C, Hizal M, Kut E, Menevse S, Sakalar T, Taskaynatan H, Deniz GI, Karaagac M, Avci O, Sen E, Karatas F, Akinci MB, Dede DS, Demir A, Demirkazık A, Oksuzoglu B, Kilickap S, Yumuk F, Yalcin B. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study. J Cancer Res Clin Oncol 2021;147:2145-52. [PMID: 33433657 DOI: 10.1007/s00432-020-03501-6] [Reference Citation Analysis]
147 Saavedra D, Crombet T. CIMAvax-EGF: A New Therapeutic Vaccine for Advanced Non-Small Cell Lung Cancer Patients. Front Immunol 2017;8:269. [PMID: 28348561 DOI: 10.3389/fimmu.2017.00269] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
148 Lai YH, Lin SY, Wu YS, Chen HW, Chen JJW. AC-93253 iodide, a novel Src inhibitor, suppresses NSCLC progression by modulating multiple Src-related signaling pathways. J Hematol Oncol 2017;10:172. [PMID: 29132432 DOI: 10.1186/s13045-017-0539-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
149 Harvey RD, Adams VR, Beardslee T, Medina P. Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings. J Oncol Pharm Pract 2020;26:1461-74. [PMID: 32567494 DOI: 10.1177/1078155220931926] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
150 Fujiwara A, Yoshida M, Fujimoto H, Nakahara H, Ito K, Nishihama K, Yasuma T, Hataji O, Taguchi O, D'Alessandro-Gabazza CN, Gabazza EC, Kobayashi T. A Retrospective Comparison of the Clinical Efficacy of Gefitinib, Erlotinib, and Afatinib in Japanese Patients With Non-Small Cell Lung Cancer. Oncol Res 2018;26:1031-6. [PMID: 29321093 DOI: 10.3727/096504018X15151523767752] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
151 Bai J, Guo F, Li M, Li Y, Lei X. Click-based amplification: designed to facilitate various target labelling modes with ultralow background amplification. RSC Chem Biol 2021;2:906-16. [PMID: 34458817 DOI: 10.1039/d1cb00002k] [Reference Citation Analysis]
152 Liu Y, Lai M, Li S, Wang Y, Feng F, Zhang T, Tong L, Zhang M, Chen H, Chen Y, Song P, Li Y, Bai G, Ning Y, Tang H, Fang Y, Chen Y, Lu X, Geng M, Ding K, Yu K, Xie H, Ding J. LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo. Cancer Sci 2021. [PMID: 34855271 DOI: 10.1111/cas.15229] [Reference Citation Analysis]
153 Su PL, Wu YL, Chang WY, Ho CL, Tseng YL, Lai WW, Su WC, Lin CC, Yang SC. Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer. Ther Adv Med Oncol 2018;10:1758835918797589. [PMID: 30263066 DOI: 10.1177/1758835918797589] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
154 Le X, Cornelissen R, Garassino M, Clarke JM, Tchekmedyian N, Goldman JW, Leu SY, Bhat G, Lebel F, Heymach JV, Socinski MA. Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial. J Clin Oncol 2021;:JCO2101323. [PMID: 34843401 DOI: 10.1200/JCO.21.01323] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
155 Chen YC, Tsai MJ, Lee MH, Kuo CY, Shen MC, Tsai YM, Chen HC, Hung JY, Huang MS, Chong IW, Yang CJ. Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations. BMC Cancer 2021;21:495. [PMID: 33941115 DOI: 10.1186/s12885-021-08235-3] [Reference Citation Analysis]
156 van der Wekken AJ, Kuiper JL, Saber A, Terpstra MM, Wei J, Hiltermann TJN, Thunnissen E, Heideman DAM, Timens W, Schuuring E, Kok K, Smit EF, van den Berg A, Groen HJM. Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression. PLoS One 2017;12:e0182885. [PMID: 28854272 DOI: 10.1371/journal.pone.0182885] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
157 Ohe Y, Imamura F, Nogami N, Okamoto I, Kurata T, Kato T, Sugawara S, Ramalingam SS, Uchida H, Hodge R, Vowler SL, Walding A, Nakagawa K. Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset. Jpn J Clin Oncol 2019;49:29-36. [PMID: 30508196 DOI: 10.1093/jjco/hyy179] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 13.7] [Reference Citation Analysis]
158 Levantini E, Maroni G, Del Re M, Tenen DG. EGFR signaling pathway as therapeutic target in human cancers. Semin Cancer Biol 2022:S1044-579X(22)00096-7. [PMID: 35427766 DOI: 10.1016/j.semcancer.2022.04.002] [Reference Citation Analysis]
159 Vu TH, Nguyen HTT, Dao LK, Duong CK, Nguyen CV, Doan TT, Nguyen HTT, Hoang HH, Dinh DK, Le GV, Vu TT, Truong MC, Nguyen LT. Effectiveness and Tolerability of First-Line Afatinib for Advanced EGFR-Mutant Non-Small Cell Lung Cancer in Vietnam. Asian Pac J Cancer Prev 2021;22:1581-90. [PMID: 34048189 DOI: 10.31557/APJCP.2021.22.5.1581] [Reference Citation Analysis]
160 Igawa S, Ono T, Kasajima M, Ishihara M, Hiyoshi Y, Kusuhara S, Nishinarita N, Fukui T, Kubota M, Sasaki J, Hisashi M, Yokoba M, Katagiri M, Naoki K. Impact of EGFR genotype on the efficacy of osimertinib in EGFR tyrosine kinase inhibitor-resistant patients with non-small cell lung cancer: a prospective observational study. Cancer Manag Res 2019;11:4883-92. [PMID: 31213907 DOI: 10.2147/CMAR.S207170] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
161 Haslam A, Herrera-Perez D, Gill J, Prasad V. Patient Experience Captured by Quality-of-Life Measurement in Oncology Clinical Trials. JAMA Netw Open 2020;3:e200363. [PMID: 32129865 DOI: 10.1001/jamanetworkopen.2020.0363] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
162 Liao BC, Lin CC, Yang JC. Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib. Curr Oncol Rep 2017;19:4. [PMID: 28138934 DOI: 10.1007/s11912-017-0560-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
163 Santos ES, Hart L. Advanced Squamous Cell Carcinoma of the Lung: Current Treatment Approaches and the Role of Afatinib. Onco Targets Ther 2020;13:9305-21. [PMID: 33061419 DOI: 10.2147/OTT.S250446] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
164 De Mello RA, Escriu C, Castelo-Branco P, Cabral PL, Mountzios G, Lopes GL, Madureira P. Comparative outcome assessment of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small-cell lung cancer: a network meta-analysis. Oncotarget 2018;9:11805-15. [PMID: 29545937 DOI: 10.18632/oncotarget.23668] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
165 Tokudome N, Koh Y, Akamatsu H, Fujimoto D, Okamoto I, Nakagawa K, Hida T, Imamura F, Morita S, Yamamoto N. Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy. BMC Cancer 2020;20:103. [PMID: 32028909 DOI: 10.1186/s12885-020-6593-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
166 Zhang T, Wan B, Zhao Y, Li C, Liu H, Lv T, Zhan P, Song Y. Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment. Transl Lung Cancer Res 2019;8:302-16. [PMID: 31367543 DOI: 10.21037/tlcr.2019.04.12] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 10.3] [Reference Citation Analysis]
167 Ntzifa A, Kotsakis A, Georgoulias V, Lianidou E. Detection of EGFR Mutations in Plasma cfDNA and Paired CTCs of NSCLC Patients before and after Osimertinib Therapy Using Crystal Digital PCR. Cancers (Basel) 2021;13:2736. [PMID: 34073111 DOI: 10.3390/cancers13112736] [Reference Citation Analysis]
168 Moehler M, Maderer A, Ehrlich A, Foerster F, Schad A, Nickolay T, Ruckes C, Weinmann A, Sivanathan V, Marquardt JU, Galle PR, Woerns M, Thomaidis T. Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program. BMC Cancer 2019;19:55. [PMID: 30634942 DOI: 10.1186/s12885-018-5223-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
169 Liam CK. The role of osimertinib in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer. J Thorac Dis 2019;11:S448-52. [PMID: 30997245 DOI: 10.21037/jtd.2018.11.45] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
170 Okuma Y, Morikawa K, Tanaka H, Yokoyama T, Itani H, Horiuchi K, Nakagawa H, Takahashi N, Bessho A, Soejima K, Kishi K, Togashi A, Kanai Y, Ueda K, Horimoto K, Matsutani N, Seki N. Prospective exosome-focused translational research for afatinib study of non-small cell lung cancer patients expressing EGFR (EXTRA study). Thorac Cancer 2019;10:395-400. [PMID: 30536780 DOI: 10.1111/1759-7714.12923] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
171 Zhang Q, Wu C, Ding W, Zhang Z, Qiu X, Mu D, Zhang H, Xi Y, Zhou J, Ma L, Fu S, Gao M, Wang B, Deng J, Lin D, Zhang J. Prevalence of ROS1 fusion in Chinese patients with non-small cell lung cancer. Thorac Cancer 2019;10:47-53. [PMID: 30468296 DOI: 10.1111/1759-7714.12899] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
172 Chen PY, Wang CC, Hsu CN, Chen CY. Association of EGFR Tyrosine Kinase Inhibitor Treatment With Progression-Free Survival Among Taiwanese Patients With Advanced Lung Adenocarcinoma and EGFR Mutation. Front Pharmacol 2021;12:720687. [PMID: 34434112 DOI: 10.3389/fphar.2021.720687] [Reference Citation Analysis]
173 Noronha V, Patil VM, Joshi A, Menon N, Chougule A, Mahajan A, Janu A, Purandare N, Kumar R, More S, Goud S, Kadam N, Daware N, Bhattacharjee A, Shah S, Yadav A, Trivedi V, Behel V, Dutt A, Banavali SD, Prabhash K. Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer. J Clin Oncol 2020;38:124-36. [PMID: 31411950 DOI: 10.1200/JCO.19.01154] [Cited by in Crossref: 136] [Cited by in F6Publishing: 67] [Article Influence: 68.0] [Reference Citation Analysis]
174 Zhou Q, Wang M, Zhang H, Hong Q, Liu X, Lu P, Su W, Wu Y. Safety and efficacy of epitinib for EGFR-mutant non-small cell lung cancer with brain metastases: open-label multicentre dose-expansion phase Ib study. Clinical Lung Cancer 2022. [DOI: 10.1016/j.cllc.2022.03.014] [Reference Citation Analysis]
175 Taslimi S, Brar K, Ellenbogen Y, Deng J, Hou W, Moraes FY, Glantz M, Zacharia BE, Tan A, Ahluwalia MS, Khasraw M, Zadeh G, Mansouri A. Comparative Efficacy of Systemic Agents for Brain Metastases From Non-Small-Cell Lung Cancer With an EGFR Mutation/ALK Rearrangement: A Systematic Review and Network Meta-Analysis. Front Oncol 2021;11:739765. [PMID: 34950579 DOI: 10.3389/fonc.2021.739765] [Reference Citation Analysis]
176 Spagnuolo A, Muto M, Monaco F, Colantuoni G, Gridelli C. The optional approach of oncogene-addicted non-small cell lung cancer with brain metastases in the new generation targeted therapies era. Transl Lung Cancer Res 2019;8:1134-51. [PMID: 32010591 DOI: 10.21037/tlcr.2019.12.24] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
177 Passaro A, de Marinis F. Dacomitinib in EGFR-positive non-small cell lung cancer: an attractive but broken option. Transl Lung Cancer Res 2018;7:S100-2. [PMID: 29780702 DOI: 10.21037/tlcr.2018.02.09] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
178 Thongprasert S, Geater SL, Clement D, Abdelaziz A, Reyes-Igama J, Jovanovic D, Alexandru A, Schenker M, Sriuranpong V, Serwatowski P, Suresh S, Cseh A, Gaafar R. Afatinib in locally advanced/metastatic NSCLC harboring common EGFR mutations, after chemotherapy: a Phase IV study. Lung Cancer Manag 2019;8:LMT15. [PMID: 31807143 DOI: 10.2217/lmt-2019-0004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
179 Hiret S, Isambert N, Gomez-Roca C, Bennouna J, Sassi M, de Mont-Serrat H, Fan J, Schnell D, Delord JP. Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors. Invest New Drugs 2018;36:1044-59. [PMID: 29808308 DOI: 10.1007/s10637-018-0601-1] [Reference Citation Analysis]
180 Díaz-Serrano A, Gella P, Jiménez E, Zugazagoitia J, Paz-Ares Rodríguez L. Targeting EGFR in Lung Cancer: Current Standards and Developments. Drugs 2018;78:893-911. [PMID: 29915896 DOI: 10.1007/s40265-018-0916-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
181 Tamiya M, Tamiya A, Okamoto N, Taniguchi Y, Nishino K, Atagi S, Hirashima T, Imamura F, Kumagai T, Suzuki H. The ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR-TKI-refractory NSCLC. Sci Rep 2021;11:9629. [PMID: 33953280 DOI: 10.1038/s41598-021-89006-9] [Reference Citation Analysis]
182 Wang S, Li J. Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer. Onco Targets Ther 2019;12:6535-48. [PMID: 31496745 DOI: 10.2147/OTT.S198945] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
183 Green JA. Osimertinib-first or second line for epidermal growth factor (EGFR) mutation-positive non-small cell lung cancer? J Thorac Dis 2018;10:S3837-9. [PMID: 30631492 DOI: 10.21037/jtd.2018.09.52] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
184 Mountzios G, Koumarianou A, Bokas A, Mavroudis D, Samantas E, Fergadis EG, Linardou H, Katsaounis P, Athanasiadis E, Karamouzis MV, Pentheroudakis G, Lampaki S, Froudarakis ME, Perdikouri EA, Somarakis A, Papageorgiou F, Paparepa Z, Nikolaou A, Syrigos KN. A Real-World, Observational, Prospective Study to Assess the Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations upon Progression on or after First-Line Therapy with a First- or Second-Generation EGFR Tyrosine Kinase Inhibitor in EGFR Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer: The 'LUNGFUL' Study. Cancers (Basel) 2021;13:3172. [PMID: 34202063 DOI: 10.3390/cancers13133172] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
185 Deeks ED, Keating GM. Afatinib in advanced NSCLC: a profile of its use. Drugs Ther Perspect 2018;34:89-98. [PMID: 29540977 DOI: 10.1007/s40267-018-0482-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
186 Mizugaki H, Oizumi S, Fujita Y, Harada T, Nakahara Y, Takashina T, Ko R, Watanabe K, Hotta T, Minemura H, Saeki S, Asahina H, Nakamura K, Nakamura H, Hosoda F, Yagishita S, Hamada A. Pharmacokinetic and pharmacogenomic analysis of low-dose afatinib treatment in elderly patients with EGFR mutation-positive non-small cell lung cancer. Eur J Cancer 2022;160:227-34. [PMID: 34862083 DOI: 10.1016/j.ejca.2021.10.024] [Reference Citation Analysis]
187 Lu S. Development of treatment options for Chinese patients with advanced squamous cell lung cancer: focus on afatinib. Onco Targets Ther 2019;12:1521-38. [PMID: 30863118 DOI: 10.2147/OTT.S188296] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
188 Yonesaka K, Iwama E, Hayashi H, Suzuki S, Kato R, Watanabe S, Takahama T, Tanizaki J, Tanaka K, Takeda M, Sakai K, Azuma K, Chiba Y, Atagi S, Nishio K, Okamoto I, Nakagawa K. Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors. Sci Rep 2019;9:19501. [PMID: 31862929 DOI: 10.1038/s41598-019-55939-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
189 Provencio M, Torrente M, Calvo V, Gutiérrez L, Pérez-Callejo D, Pérez-Barrios C, Barquín M, Royuela A, Rodriguez-Alfonso B, Sotelo M, Cruz-Bermúdez JL, Mendez M, Cruz-Bermúdez A, Romero A. Dynamic circulating tumor DNA quantificaton for the individualization of non-small-cell lung cancer patients treatment. Oncotarget 2017;8:60291-8. [PMID: 28947971 DOI: 10.18632/oncotarget.20016] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
190 Nakamura T, Nakashima C, Komiya K, Kitera K, Hirai M, Kimura S, Aragane N. Mechanisms of acquired resistance to afatinib clarified with liquid biopsy. PLoS One 2018;13:e0209384. [PMID: 30550608 DOI: 10.1371/journal.pone.0209384] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
191 Puliafito I, Esposito F, Raciti G, Giuffrida P, Caltavuturo C, Colarossi C, Munao S, Sciacca D, Giuffrida D. Metabolic complete tumor response in a patient with epidermal growth factor receptor mutant non-small cell lung cancer treated with a reduced dose of afatinib. J Int Med Res 2022;50:3000605211058864. [PMID: 35291829 DOI: 10.1177/03000605211058864] [Reference Citation Analysis]
192 Okajima M, Miura S, Watanabe S, Tanaka H, Ito K, Ishida T, Makino M, Iwashima A, Matsumoto N, Sato K, Ichikawa K, Abe T, Yoshizawa H, Kikuchi T. A prospective phase II study of multimodal prophylactic treatment for afatinib-induced adverse events in advanced non-small cell lung cancer (Niigata Lung Cancer Treatment Group 1401). Transl Lung Cancer Res 2021;10:252-60. [PMID: 33569309 DOI: 10.21037/tlcr-20-649] [Reference Citation Analysis]
193 Huang YH, Hung JY, Ko HW, Su PL, Lai CL, Chang HC, Hsia TC, Lin SH, Wu KL, Yang CT, Su WC, Chu YC, Wang CC, Liao WY, Lin YT, Lin CH, Lin MC, Hsu KH, Tseng JS, Yang TY, Chen KC, Lee MH, Yu SL, Ho CC, Chang GC. The relative importance of predictive factors for single first-generation EGFR-TKI use for more than 5 years in patients with advanced non-small cell lung cancer: Taiwan multicenter TIPS-5 study. Ther Adv Med Oncol 2021;13:17588359211018022. [PMID: 34093743 DOI: 10.1177/17588359211018022] [Reference Citation Analysis]
194 Tan PT, Aziz MIA, Pearce F, Lim WT, Wu DB, Ng K. Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective. BMC Cancer 2018;18:352. [PMID: 29587666 DOI: 10.1186/s12885-018-4223-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
195 Łukasik P, Baranowska-Bosiacka I, Kulczycka K, Gutowska I. Inhibitors of Cyclin-Dependent Kinases: Types and Their Mechanism of Action. Int J Mol Sci 2021;22:2806. [PMID: 33802080 DOI: 10.3390/ijms22062806] [Reference Citation Analysis]
196 Aguiar P Jr, Roitberg F, Lopes G Jr, Giglio AD. Distinct models to assess the cost-effectiveness of EGFR-tyrosine kinase inhibitors for the treatment of metastatic non-small cell lung cancer in the context of the Brazilian Unified Health Care System. J Bras Pneumol 2020;46:e20180255. [PMID: 32490907 DOI: 10.36416/1806-3756/e20180255] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
197 Kim EY, Kim A, Lee G, Lee H, Chang YS. Different mutational characteristics of the subsets of EGFR-tyrosine kinase inhibitor sensitizing mutation-positive lung adenocarcinoma. BMC Cancer 2018;18:1221. [PMID: 30522449 DOI: 10.1186/s12885-018-5116-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
198 Bui KT, Cooper WA, Kao S, Boyer M. Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists. J Clin Med 2018;7:E192. [PMID: 30065223 DOI: 10.3390/jcm7080192] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
199 König D, Savic Prince S, Rothschild SI. Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations. Cancers (Basel) 2021;13:804. [PMID: 33671873 DOI: 10.3390/cancers13040804] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
200 Yu YF, Luan L, Zhu FF, Dong P, Ma LH, Li LT, Gao L, Lu S. Modelled Economic Analysis for Dacomitinib-A Cost Effectiveness Analysis in Treating Patients With EGFR-Mutation-Positive Non-Small Cell Lung Cancer in China. Front Oncol 2021;11:564234. [PMID: 34970476 DOI: 10.3389/fonc.2021.564234] [Reference Citation Analysis]
201 Ko R, Shukuya T, Imamura CK, Tokito T, Shimada N, Koyama R, Yamada K, Ishii H, Azuma K, Takahashi K. Phase I study of afatinib plus bevacizumab in patients with advanced non-squamous non-small cell lung cancer harboring EGFR mutations. Transl Lung Cancer Res 2021;10:183-92. [PMID: 33569303 DOI: 10.21037/tlcr-20-824] [Reference Citation Analysis]
202 Ono T, Igawa S, Ozawa T, Kasajima M, Ishihara M, Hiyoshi Y, Kusuhara S, Nishinarita N, Fukui T, Kubota M, Sasaki J, Hisashi M, Katagiri M, Naoki K. Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non-small cell lung cancer harboring an EGFR mutation: A prospective observational study. Thorac Cancer 2019;10:880-9. [PMID: 30821083 DOI: 10.1111/1759-7714.13018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
203 Jiang SX, Walton RN, Hueniken K, Baek J, McCartney A, Labbé C, Smith E, Chan SWS, Chen R, Brown C, Patel D, Liang M, Eng L, Sacher A, Bradbury P, Leighl NB, Shepherd FA, Xu W, Liu G, Hurry M, O'Kane GM. Real-world health utility scores and toxicities to tyrosine kinase inhibitors in epidermal growth factor receptor mutated advanced non-small cell lung cancer. Cancer Med 2019;8:7542-55. [PMID: 31650705 DOI: 10.1002/cam4.2603] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
204 Fassunke J, Müller F, Keul M, Michels S, Dammert MA, Schmitt A, Plenker D, Lategahn J, Heydt C, Brägelmann J, Tumbrink HL, Alber Y, Klein S, Heimsoeth A, Dahmen I, Fischer RN, Scheffler M, Ihle MA, Priesner V, Scheel AH, Wagener S, Kron A, Frank K, Garbert K, Persigehl T, Püsken M, Haneder S, Schaaf B, Rodermann E, Engel-Riedel W, Felip E, Smit EF, Merkelbach-Bruse S, Reinhardt HC, Kast SM, Wolf J, Rauh D, Büttner R, Sos ML. Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors. Nat Commun 2018;9:4655. [PMID: 30405134 DOI: 10.1038/s41467-018-07078-0] [Cited by in Crossref: 43] [Cited by in F6Publishing: 47] [Article Influence: 10.8] [Reference Citation Analysis]
205 Mitsudomi T, Kobayashi Y. Afatinib in lung cancer harboring EGFR mutation in the LUX-Lung trials: six plus three is greater than seven? Transl Lung Cancer Res 2016;5:446-9. [PMID: 27650363 DOI: 10.21037/tlcr.2016.07.06] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
206 Keating GM. Afatinib: A Review in Advanced Non-Small Cell Lung Cancer. Target Oncol 2016;11:825-35. [PMID: 27873136 DOI: 10.1007/s11523-016-0465-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
207 Codony-Servat C, Codony-Servat J, Karachaliou N, Molina MA, Chaib I, Ramirez JL, de Los Llanos Gil M, Solca F, Bivona TG, Rosell R. Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC). Oncotarget 2017;8:47305-16. [PMID: 28521301 DOI: 10.18632/oncotarget.17625] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 6.0] [Reference Citation Analysis]
208 He G, Jiang Z, Xue S, Sun X, Wang W. Expression of LDH and CEA in serum in the process of targeted therapy of lung adenocarcinoma and the association between them and prognosis. Oncol Lett 2019;17:4550-6. [PMID: 30944644 DOI: 10.3892/ol.2019.10115] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
209 Castañeda-Zárraga A, Rodríguez-Cid JR, Flores-Mariñelarena RR, Trinidad-Bibiano H, Martínez-Herrera JF, Sánchez-Ríos CP, Fernández-Garibay VM, Alatorre-Alexander JA, Martínez-Barrera L, Santillán-Doherty PJ, Vega-Memije ME. Human skin biomarkers relationship to response to treatment with tyrosine kinase inhibitors in advanced EGFR-mutated lung adenocarcinoma. Thorac Cancer 2020;11:3243-51. [PMID: 33015988 DOI: 10.1111/1759-7714.13657] [Reference Citation Analysis]
210 Morin-Ben Abdallah S, Hirsh V. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treatment of Metastatic Non-Small Cell Lung Cancer, with a Focus on Afatinib. Front Oncol 2017;7:97. [PMID: 28560182 DOI: 10.3389/fonc.2017.00097] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
211 Guo L, Li X, Liu R, Chen Y, Ren C, Du S. TOX correlates with prognosis, immune infiltration, and T cells exhaustion in lung adenocarcinoma. Cancer Med 2020;9:6694-709. [PMID: 32700817 DOI: 10.1002/cam4.3324] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
212 Pulito C, Cristaudo A, Porta C, Zapperi S, Blandino G, Morrone A, Strano S. Oral mucositis: the hidden side of cancer therapy. J Exp Clin Cancer Res 2020;39:210. [PMID: 33028357 DOI: 10.1186/s13046-020-01715-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
213 Ahn BC, Lee JH, Kim MH, Pyo KH, Lee CK, Lim SM, Kim HR, Cho BC, Hong MH. Distinct Characteristics and Clinical Outcomes to Predict the Emergence of MET Amplification in Patients with Non-Small Cell Lung Cancer Who Developed Resistance after Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Cancers (Basel) 2021;13:3096. [PMID: 34205733 DOI: 10.3390/cancers13123096] [Reference Citation Analysis]
214 Zhang W, Li F, Gao W. New data highlighting the efficacy and safety outcomes of third-generation EGFR-TKI in NSCLC patients with rare EGFR mutations. Thorac Cancer 2020;11:495-7. [PMID: 31989783 DOI: 10.1111/1759-7714.13334] [Reference Citation Analysis]
215 Lazaro T, Brastianos PK. Immunotherapy and targeted therapy in brain metastases: emerging options in precision medicine. CNS Oncol 2017;6:139-51. [PMID: 28425754 DOI: 10.2217/cns-2016-0038] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
216 Qian J, Zhang X, Zhang B, Gu P, Wang L, Han B. Hepatotoxicity in Advanced Lung Adenocarcinoma: A Retrospective Study of 2108 Cases. J Cancer 2018;9:1607-13. [PMID: 29760799 DOI: 10.7150/jca.24217] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
217 Lu T, Li Q, Li L, Yang K, Zhou D, Gao J, Chen M, Xu Y, Zhong W, Wang M, Liang Z, Zhao J. [Results of EGFR Mutations Detected in Pleural Effusion and Its 
Clinical Significance in 132 Patients with Advanced Non-small Cell Lung Cancer: 
A Retrospective Study in A Single Center]. Zhongguo Fei Ai Za Zhi 2020;23:1059-65. [PMID: 33357312 DOI: 10.3779/j.issn.1009-3419.2020.104.23] [Reference Citation Analysis]
218 Bahleda R, Varga A, Bergé Y, Soria JC, Schnell D, Tschoepe I, Uttenreuther-Fischer M, Delord JP. Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2. Br J Cancer 2018;118:344-52. [PMID: 29337963 DOI: 10.1038/bjc.2017.436] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
219 Park K. Afatinib for patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer: clinical implications of the LUX-Lung 7 study. Ann Transl Med 2016;4:476. [PMID: 28090532 DOI: 10.21037/atm.2016.11.42] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
220 Ferrara MG, Di Noia V, D'Argento E, Vita E, Damiano P, Cannella A, Ribelli M, Pilotto S, Milella M, Tortora G, Bria E. Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives. Cancers (Basel) 2020;12:E1196. [PMID: 32397295 DOI: 10.3390/cancers12051196] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 9.5] [Reference Citation Analysis]
221 Albaba H, Lim C, Leighl NB. Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature. Pharmacoeconomics 2017;35:1195-209. [PMID: 28861770 DOI: 10.1007/s40273-017-0563-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
222 Xiao N, He H, Wang J, Zhang L, Chow B, Feng F, Xu Y, Huang J, Zhou X, Dong R. Meta-Analysis of Aidi Injection and First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy in Treating Advanced Non-Small Cell Lung Cancer. J Evid Based Integr Med 2021;26:2515690X211010733. [PMID: 33926244 DOI: 10.1177/2515690X211010733] [Reference Citation Analysis]
223 Ho GF, Chai CS, Alip A, Wahid MIA, Abdullah MM, Foo YC, How SH, Zaatar A, Lam KS, Leong KW, Low JS, Yusof MM, Lee EC, Toh YY, Liam CK. Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study. BMC Cancer. 2019;19:896. [PMID: 31500587 DOI: 10.1186/s12885-019-6107-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
224 Vigarios E, Epstein JB, Sibaud V. Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. Support Care Cancer 2017;25:1713-39. [PMID: 28224235 DOI: 10.1007/s00520-017-3629-4] [Cited by in Crossref: 65] [Cited by in F6Publishing: 51] [Article Influence: 13.0] [Reference Citation Analysis]
225 Zugazagoitia J, Díaz A, Jimenez E, Nuñez JA, Iglesias L, Ponce-Aix S, Paz-Ares L. Second-line Treatment of Non-Small Cell Lung Cancer: Focus on the Clinical Development of Dacomitinib. Front Med (Lausanne) 2017;4:36. [PMID: 28424775 DOI: 10.3389/fmed.2017.00036] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
226 Osoegawa A, Yamaguchi M, Nakamura T, Morinaga R, Tanaka K, Kashiwabara K, Miura T, Suetsugu T, Harada T, Asoh T, Taguchi K, Nabeshima K, Kishimoto J, Sakai K, Nishio K, Sugio K. High Incidence of C797S Mutation in Patients With Long Treatment History of EGFR Tyrosine Kinase Inhibitors Including Osimertinib. JTO Clin Res Rep 2021;2:100191. [PMID: 34590037 DOI: 10.1016/j.jtocrr.2021.100191] [Reference Citation Analysis]
227 Inomata M, Matsumoto M, Mizushima I, Hayashi K, Seto Z, Tokui K, Taka C, Okazawa S, Kambara K, Imanishi S, Miwa T, Hayashi R, Matsui S, Tobe K. Impact of sequential therapy with osimertinib on the overall survival in patients with EGFR-mutant non-small cell lung cancer. Egypt J Bronchol 2022;16. [DOI: 10.1186/s43168-022-00121-1] [Reference Citation Analysis]
228 Kolesar J, Peh S, Thomas L, Baburaj G, Mukherjee N, Kantamneni R, Lewis S, Pai A, Udupa KS, Kumar An N, Rangnekar VM, Rao M. Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers. Mol Cancer 2022;21:61. [PMID: 35209919 DOI: 10.1186/s12943-022-01534-8] [Reference Citation Analysis]
229 Huang CY, Chen BH, Chou WC, Yang CT, Chang JW. Factors associated with the prognosis and long-term survival of patients with metastatic lung adenocarcinoma: a retrospective analysis. J Thorac Dis 2018;10:2070-8. [PMID: 29850110 DOI: 10.21037/jtd.2018.03.143] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
230 Ninomiya K, Teraoka S, Zenke Y, Kenmotsu H, Nakamura Y, Okuma Y, Tamiya A, Nosaki K, Morise M, Aokage K, Oya Y, Kozuki T, Sakamoto T, Tanaka K, Tanaka H, Tanizaki J, Miura S, Mizutani H, Miyauchi E, Yamaguchi O, Ebi N, Goto Y, Sasaki T, Daga H, Morita S, Yamanaka T, Amano S, Hasegawa K, Imamura CK, Suzuki K, Nakajima K, Nishimoto H, Oizumi S, Hida T, Hotta K, Takiguchi Y. Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations. JTO Clin Res Rep 2021;2:100107. [PMID: 34589972 DOI: 10.1016/j.jtocrr.2020.100107] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
231 Nagano T, Tachihara M, Nishimura Y. Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy. Cells 2018;7:E212. [PMID: 30445769 DOI: 10.3390/cells7110212] [Cited by in Crossref: 77] [Cited by in F6Publishing: 85] [Article Influence: 19.3] [Reference Citation Analysis]
232 Takahashi T, Terazono H, Suetsugu T, Sugawara H, Arima J, Nitta M, Tanabe T, Okutsu K, Ikeda R, Mizuno K, Inoue H, Takeda Y. High-Trough Plasma Concentration of Afatinib Is Associated with Dose Reduction. Cancers (Basel) 2021;13:3425. [PMID: 34298637 DOI: 10.3390/cancers13143425] [Reference Citation Analysis]
233 Milton AV, Konrad DB. Epithelial-mesenchymal transition and H2O2 signaling - a driver of disease progression and a vulnerability in cancers. Biol Chem 2022. [PMID: 35032422 DOI: 10.1515/hsz-2021-0341] [Reference Citation Analysis]
234 Tian X, Gu T, Lee MH, Dong Z. Challenge and countermeasures for EGFR targeted therapy in non-small cell lung cancer. Biochim Biophys Acta Rev Cancer 2021;1877:188645. [PMID: 34793897 DOI: 10.1016/j.bbcan.2021.188645] [Reference Citation Analysis]
235 Tan J, Hu C, Deng P, Wan R, Cao L, Li M, Yang H, Gu Q, An J, Jiang J. The Predictive Values of Advanced Non-Small Cell Lung Cancer Patients Harboring Uncommon EGFR Mutations-The Mutation Patterns, Use of Different Generations of EGFR-TKIs, and Concurrent Genetic Alterations. Front Oncol 2021;11:646577. [PMID: 34513661 DOI: 10.3389/fonc.2021.646577] [Reference Citation Analysis]
236 Bebb DG, Banerji S, Blais N, Desmeules P, Gill S, Grin A, Feilotter H, Hansen AR, Hyrcza M, Krzyzanowska M, Melosky B, Noujaim J, Purgina B, Ruether D, Simmons CE, Soulieres D, Torlakovic EE, Tsao MS. Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults. Curr Oncol 2021;28:523-48. [PMID: 33467570 DOI: 10.3390/curroncol28010053] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
237 Li CL, Hsia TC, Yang ST, Chao KC, Tu CY, Chen HJ, Li CH. Efficacy of Prophylactic Traditional Chinese Medicine on Skin Toxicity of Afatinib in EGFR Mutation-Positive Advanced Lung Adenocarcinoma: A Single-Center, Prospective, Double-Blinded, Randomized-Controlled Pilot Trial. Integr Cancer Ther 2022;21:15347354221086663. [PMID: 35297709 DOI: 10.1177/15347354221086663] [Reference Citation Analysis]
238 Haeussler K, Wang X, Winfree KB, D'yachkova Y, Traore S, Puri T, Thom H, Papagiannopoulos C, Nassim M, Taipale K. Efficacy and safety of first-line therapies in EGFR-mutated advanced non-small-cell lung cancer: a network meta-analysis. Future Oncol 2022. [PMID: 35187947 DOI: 10.2217/fon-2021-0885] [Reference Citation Analysis]
239 Qian J, Zhang X, Zhang B, Yan B, Wang L, Gu P, Wang W, Wang H, Han B. Tyrosine Kinase Inhibitor-Related Hepatotoxicity in Patients with Advanced Lung Adenocarcinoma: A Real-World Retrospective Study. Cancer Manag Res 2020;12:3293-9. [PMID: 32494193 DOI: 10.2147/CMAR.S237968] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
240 Bansal P, Osman D, Gan GN, Simon GR, Boumber Y. Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC. Front Oncol 2016;6:112. [PMID: 27200298 DOI: 10.3389/fonc.2016.00112] [Cited by in Crossref: 3] [Cited by in F6Publishing: 17] [Article Influence: 0.5] [Reference Citation Analysis]
241 Ikeuchi H, Hirose T, Ikegami M, Takamochi K, Suzuki K, Mano H, Kohsaka S. Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model. Oncogene 2022. [PMID: 35304574 DOI: 10.1038/s41388-022-02263-4] [Reference Citation Analysis]
242 O'Kane GM, Barnes TA, Leighl NB. Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials. Curr Oncol 2018;25:S28-37. [PMID: 29910645 DOI: 10.3747/co.25.3796] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
243 Westerink L, Nicolai JLJ, Samuelsen C, Smit HJM, Postmus PE, Griebsch I, Postma MJ. Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations. Eur J Health Econ 2020;21:931-43. [PMID: 32328874 DOI: 10.1007/s10198-020-01186-9] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
244 Minchom A, Thavasu P, Ahmad Z, Stewart A, Georgiou A, O'Brien MER, Popat S, Bhosle J, Yap TA, de Bono J, Banerji U. A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments. PLoS One 2017;12:e0186106. [PMID: 28982179 DOI: 10.1371/journal.pone.0186106] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
245 Li J, Kwok HF. Current Strategies for Treating NSCLC: From Biological Mechanisms to Clinical Treatment. Cancers (Basel) 2020;12:E1587. [PMID: 32549388 DOI: 10.3390/cancers12061587] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
246 Kashima J, Kitadai R, Okuma Y. Molecular and Morphological Profiling of Lung Cancer: A Foundation for "Next-Generation" Pathologists and Oncologists. Cancers (Basel) 2019;11:E599. [PMID: 31035693 DOI: 10.3390/cancers11050599] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
247 Watanabe K, Kage H, Nagoshi S, Toyama K, Ohno Y, Shinozaki-Ushiku A, Nakazaki K, Suzuki H, Kurokawa M, Nagase T. Dual EGFR and ABL Tyrosine Kinase Inhibitor Treatment in a Patient with Concomitant EGFR-Mutated Lung Adenocarcinoma and BCR-ABL1-Positive CML. Case Rep Oncol Med 2020;2020:4201727. [PMID: 32257476 DOI: 10.1155/2020/4201727] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
248 Long MJC, Aye Y. Privileged Electrophile Sensors: A Resource for Covalent Drug Development. Cell Chem Biol 2017;24:787-800. [PMID: 28648380 DOI: 10.1016/j.chembiol.2017.05.023] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 8.0] [Reference Citation Analysis]
249 Sakanoue I, Hamakawa H, Kaji R, Imai Y, Katakami N, Takahashi Y. Sleeve lobectomy for lung adenocarcinoma treated with neoadjuvant afatinib. J Thorac Dis 2018;10:E170-4. [PMID: 29707366 DOI: 10.21037/jtd.2018.02.03] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
250 Tsubata Y, Tanino R, Isobe T. Current Therapeutic Strategies and Prospects for EGFR Mutation-Positive Lung Cancer Based on the Mechanisms Underlying Drug Resistance. Cells 2021;10:3192. [PMID: 34831415 DOI: 10.3390/cells10113192] [Reference Citation Analysis]
251 Xie T, Zou Z, Liu C, Zhu Y, Xu Z, Wang L, Li J, Xing P. Front-Line Therapy in EGFR Exon 19 Deletion and 21 Leu858Arg Mutations in Advanced Non-Small Cell Lung Cancer: A Network Meta-Analysis. Evid Based Complement Alternat Med 2021;2021:9311875. [PMID: 34938345 DOI: 10.1155/2021/9311875] [Reference Citation Analysis]
252 Vogelbaum MA, Brown PD, Messersmith H, Brastianos PK, Burri S, Cahill D, Dunn IF, Gaspar LE, Gatson NTN, Gondi V, Jordan JT, Lassman AB, Maues J, Mohile N, Redjal N, Stevens G, Sulman E, van den Bent M, Wallace HJ, Weinberg JS, Zadeh G, Schiff D. Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. J Clin Oncol 2021;:JCO2102314. [PMID: 34932393 DOI: 10.1200/JCO.21.02314] [Reference Citation Analysis]
253 Yang SC, Lai WW, Hsu JC, Su WC, Wang JD. Comparative effectiveness and cost-effectiveness of three first-line EGFR-tyrosine kinase inhibitors: Analysis of real-world data in a tertiary hospital in Taiwan. PLoS One 2020;15:e0231413. [PMID: 32267879 DOI: 10.1371/journal.pone.0231413] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
254 Della Corte CM, Malapelle U, Vigliar E, Pepe F, Troncone G, Ciaramella V, Troiani T, Martinelli E, Belli V, Ciardiello F, Morgillo F. Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR. Oncotarget 2017;8:23020-32. [PMID: 28416737 DOI: 10.18632/oncotarget.15479] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
255 Nakao K, Kobuchi S, Marutani S, Iwazaki A, Tamiya A, Isa S, Okishio K, Kanazu M, Tamiya M, Hirashima T, Imai K, Sakaeda T, Atagi S. Population pharmacokinetics of afatinib and exposure-safety relationships in Japanese patients with EGFR mutation-positive non-small cell lung cancer. Sci Rep 2019;9:18202. [PMID: 31796841 DOI: 10.1038/s41598-019-54804-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
256 Passaro A, de Marinis F, Tu HY, Laktionov KK, Feng J, Poltoratskiy A, Zhao J, Tan EH, Gottfried M, Lee V, Kowalski D, Yang CT, Srinivasa BJ, Clementi L, Jalikop T, Huang DCL, Cseh A, Park K, Wu YL. Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies. Front Oncol 2021;11:709877. [PMID: 34307179 DOI: 10.3389/fonc.2021.709877] [Reference Citation Analysis]
257 Yokota H, Sato K, Sakamoto S, Okuda Y, Asano M, Takeda M, Nakayama K, Miura M. Relationship between Plasma Concentrations of Afatinib and the Onset of Diarrhea in Patients with Non-Small Cell Lung Cancer. Biology (Basel) 2021;10:1054. [PMID: 34681153 DOI: 10.3390/biology10101054] [Reference Citation Analysis]
258 Tu CY, Chen CM, Liao WC, Wu BR, Chen CY, Chen WC, Hsia TC, Cheng WC, Chen CH. Comparison of the effects of the three major tyrosine kinase inhibitors as first-line therapy for non-small-cell lung cancer harboring epidermal growth factor receptor mutations. Oncotarget 2018;9:24237-47. [PMID: 29849936 DOI: 10.18632/oncotarget.24386] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
259 Park CK, Lee SY, Lee JC, Choi CM, Lee SY, Jang TW, Oh IJ, Kim YC. Phase II open-label multicenter study to assess the antitumor activity of afatinib in lung cancer patients with activating epidermal growth factor receptor mutation from circulating tumor DNA: Liquid-Lung-A. Thorac Cancer 2021;12:444-52. [PMID: 33270375 DOI: 10.1111/1759-7714.13763] [Reference Citation Analysis]
260 Cheng H, Planken S. Precedence and Promise of Covalent Inhibitors of EGFR and KRAS for Patients with Non-Small-Cell Lung Cancer. ACS Med Chem Lett 2018;9:861-3. [PMID: 30258528 DOI: 10.1021/acsmedchemlett.8b00311] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
261 Chinese Society of Lung Cancer, Chinese Anti-Cancer Association. [EGFR-TKI ADR Management Chinese Expert Consensus]. Zhongguo Fei Ai Za Zhi 2019;22:57-81. [PMID: 30827323 DOI: 10.3779/j.issn.1009-3419.2019.02.01] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
262 Chang SC, Lai YC, Chang CY, Huang LK, Chen SJ, Tan KT, Yu PN, Lai JI. Concomitant Genetic Alterations are Associated with Worse Clinical Outcome in EGFR Mutant NSCLC Patients Treated with Tyrosine Kinase Inhibitors. Transl Oncol 2019;12:1425-31. [PMID: 31401335 DOI: 10.1016/j.tranon.2019.07.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
263 Lau SCM, Batra U, Mok TSK, Loong HH. Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer. Drugs 2019;79:823-31. [PMID: 31069718 DOI: 10.1007/s40265-019-01115-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
264 Van Der Steen N, Caparello C, Rolfo C, Pauwels P, Peters GJ, Giovannetti E. New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong? Onco Targets Ther 2016;9:6065-74. [PMID: 27785053 DOI: 10.2147/OTT.S97644] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
265 To C, Beyett TS, Jang J, Feng WW, Bahcall M, Haikala HM, Shin BH, Heppner DE, Rana JK, Leeper BA, Soroko KM, Poitras MJ, Gokhale PC, Kobayashi Y, Wahid K, Kurppa KJ, Gero TW, Cameron MD, Ogino A, Mushajiang M, Xu C, Zhang Y, Scott DA, Eck MJ, Gray NS, Jänne PA. An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer. Nat Cancer 2022;3:402-17. [PMID: 35422503 DOI: 10.1038/s43018-022-00351-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
266 Khrystolubova N, Shieh M, Patel AJ, Bailey R. Pharmacist-led patient education and adverse event management in patients with non-small cell lung cancer receiving afatinib in a community-based, real-world clinical setting. J Oncol Pharm Pract 2020;26:13-22. [PMID: 30832554 DOI: 10.1177/1078155219833441] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
267 Qian Y, Gong Y, Fan Z, Luo G, Huang Q, Deng S, Cheng H, Jin K, Ni Q, Yu X, Liu C. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma. J Hematol Oncol 2020;13:130. [PMID: 33008426 DOI: 10.1186/s13045-020-00958-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
268 Haranguș A, Berindan-Neagoe I, Todea DA, Șimon I, Șimon M. Noncoding RNAs and Liquid Biopsy in Lung Cancer: A Literature Review. Diagnostics (Basel) 2019;9:E216. [PMID: 31818027 DOI: 10.3390/diagnostics9040216] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
269 Huang L, Jiang S, Shi Y. Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020). J Hematol Oncol 2020;13:143. [PMID: 33109256 DOI: 10.1186/s13045-020-00977-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 10.5] [Reference Citation Analysis]
270 Xie X, Wang X, Wu S, Yang H, Liu J, Chen H, Ding Y, Ling L, Lin H. Fatal toxic effects related to EGFR tyrosine kinase inhibitors based on 53 cohorts with 9,569 participants. J Thorac Dis 2020;12:4057-69. [PMID: 32944317 DOI: 10.21037/jtd-19-4000A] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
271 Arrieta O, Catalán R, Guzmán-Vazquez S, Barrón F, Lara-Mejía L, Soto-Molina H, Ramos-Ramírez M, Flores-Estrada D, de la Garza J. Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations. BMC Cancer 2020;20:829. [PMID: 32873256 DOI: 10.1186/s12885-020-07329-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
272 Maarof NNN, Alsalahi A, Abdulmalek E, Fakurazi S, Tejo BA, Abdul Rahman MB. Efficacy of Afatinib in the Treatment of Patients with Non-Small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis. Cancers (Basel) 2021;13:688. [PMID: 33567737 DOI: 10.3390/cancers13040688] [Reference Citation Analysis]
273 Zhao B, Wang Y, Wang Y, Chen W, Zhou L, Liu PH, Kong Z, Dai C, Wang Y, Ma W. Efficacy and safety of therapies for EGFR-mutant non-small cell lung cancer with brain metastasis: an evidence-based Bayesian network pooled study of multivariable survival analyses. Aging (Albany NY) 2020;12:14244-70. [PMID: 32669477 DOI: 10.18632/aging.103455] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
274 Wei YF, Huang WT, Liu TC, Shieh JM, Chian CF, Wu MF, Chang CC, Lin CH, Ko JC, Lin CM, Hsia TC. Factors associated with improvement in symptoms and quality of life for first-line EGFR-tyrosine kinase inhibitor treatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter prospective SMILE study. J Cancer 2019;10:4151-8. [PMID: 31417660 DOI: 10.7150/jca.30507] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
275 An N, Zhang Y, Niu H, Li Z, Cai J, Zhao Q, Li Q. EGFR-TKIs versus taxanes agents in therapy for nonsmall-cell lung cancer patients: A PRISMA-compliant systematic review with meta-analysis and meta-regression. Medicine (Baltimore) 2016;95:e5601. [PMID: 27977598 DOI: 10.1097/MD.0000000000005601] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
276 Remon J, Besse B. Unravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment options. ESMO Open 2016;1:e000081. [PMID: 27843631 DOI: 10.1136/esmoopen-2016-000081] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
277 Li B, Yuan Z, Jiang J, Rao Y. Anti-tumor activity of Shikonin against afatinib resistant non-small cell lung cancer via negative regulation of PI3K/Akt signaling pathway. Biosci Rep 2018;38:BSR20181693. [PMID: 30420490 DOI: 10.1042/BSR20181693] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
278 Yang JJ, Zhou Q, Yan HH, Zhang XC, Chen HJ, Tu HY, Wang Z, Xu CR, Su J, Wang BC, Jiang BY, Bai XY, Zhong WZ, Yang XN, Wu YL. A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations. Br J Cancer 2017;116:568-74. [PMID: 28103612 DOI: 10.1038/bjc.2016.456] [Cited by in Crossref: 94] [Cited by in F6Publishing: 97] [Article Influence: 18.8] [Reference Citation Analysis]
279 Mendoza DP, Piotrowska Z, Lennerz JK, Digumarthy SR. Role of imaging biomarkers in mutation-driven non-small cell lung cancer. World J Clin Oncol 2020; 11(7): 412-427 [PMID: 32821649 DOI: 10.5306/wjco.v11.i7.412] [Reference Citation Analysis]
280 González-Larriba JL, Lázaro-Quintela M, Cobo M, Dómine M, Majem M, García-Campelo R. Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth factor receptor tyrosine kinase inhibitors: the necessity of repeated molecular analysis. Transl Lung Cancer Res 2017;6:S21-34. [PMID: 29299405 DOI: 10.21037/tlcr.2017.10.03] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
281 Park S, Lee SY, Kim D, Sim YS, Ryu JS, Choi J, Lee SH, Ryu YJ, Lee JH, Chang JH. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types. BMC Cancer 2021;21:52. [PMID: 33430803 DOI: 10.1186/s12885-020-07765-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
282 Wang J, Wu L. An evaluation of aumolertinib for the treatment of EGFR T790M mutation-positive non-small cell lung cancer. Expert Opin Pharmacother 2022;:1-6. [PMID: 35272542 DOI: 10.1080/14656566.2022.2050213] [Reference Citation Analysis]
283 Yu J, Fang T, Yun C, Liu X, Cai X. Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers. Front Mol Biosci 2022;9:847835. [DOI: 10.3389/fmolb.2022.847835] [Reference Citation Analysis]
284 Kim H, Jung HA, Lee SH, Ahn JS, Ahn MJ, Park K, Sun JM. Comprehensive evaluation of the clinical utility of plasma EGFR test in non-small cell lung cancer patients with acquired resistance to first-line EGFR inhibitors. Transl Lung Cancer Res 2021;10:878-88. [PMID: 33718029 DOI: 10.21037/tlcr-20-1128] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
285 Wu R, Yu S, Ye J, Wang Y, Zhao Z, Liu H, Song Y. A Multicenter Retrospective Study on the Prognosis of Stage III Unresectable Mutant Non-Small Cell Lung Cancer With Tyrosine Kinase Inhibitors Therapy. Front Oncol 2021;11:692703. [PMID: 34322390 DOI: 10.3389/fonc.2021.692703] [Reference Citation Analysis]
286 Lavacchi D, Mazzoni F, Giaccone G. Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives. Drug Des Devel Ther 2019;13:3187-98. [PMID: 31564835 DOI: 10.2147/DDDT.S194231] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
287 Hochmair MJ, Buder A, Schwab S, Burghuber OC, Prosch H, Hilbe W, Cseh A, Fritz R, Filipits M. Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib. Target Oncol 2019;14:75-83. [PMID: 30539501 DOI: 10.1007/s11523-018-0612-z] [Cited by in Crossref: 49] [Cited by in F6Publishing: 56] [Article Influence: 24.5] [Reference Citation Analysis]
288 De Pauw I, Lardon F, Van den Bossche J, Baysal H, Pauwels P, Peeters M, Vermorken JB, Wouters A. Overcoming Intrinsic and Acquired Cetuximab Resistance in RAS Wild-Type Colorectal Cancer: An In Vitro Study on the Expression of HER Receptors and the Potential of Afatinib. Cancers (Basel) 2019;11:E98. [PMID: 30650638 DOI: 10.3390/cancers11010098] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
289 O'Leary C, Gasper H, Sahin KB, Tang M, Kulasinghe A, Adams MN, Richard DJ, O'Byrne KJ. Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC). Pharmaceuticals (Basel) 2020;13:E273. [PMID: 32992872 DOI: 10.3390/ph13100273] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
290 Tan AC, Tan DSW. Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations. J Clin Oncol 2022;40:611-25. [PMID: 34985916 DOI: 10.1200/JCO.21.01626] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 9.0] [Reference Citation Analysis]
291 Choi JH, Choi YW, Lee HW, Kang SY, Jeong GS, Ahn MS, Oh YT, Noh OK, Kim SH, Roh TH, Sheen SS. The efficacy of EGFR-tyrosine kinase inhibitor in non-small cell lung cancer patients with synchronous brain metastasis: a real-world study. Korean J Intern Med 2022. [PMID: 35167736 DOI: 10.3904/kjim.2021.315] [Reference Citation Analysis]
292 Peng Z, Lin H, Zhou K, Deng S, Mei J. Predictive value of pretreatment PD-L1 expression in EGFR-mutant non-small cell lung cancer: a meta-analysis. World J Surg Oncol 2021;19:145. [PMID: 33964931 DOI: 10.1186/s12957-021-02254-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
293 Ito K, Hataji O. Osimertinib therapy as first-line treatment before acquiring T790M mutation: from AURA1 trial. J Thorac Dis 2018;10:S3071-7. [PMID: 30430025 DOI: 10.21037/jtd.2018.07.52] [Reference Citation Analysis]
294 Zhu Y, Li L, Zhang P, Zuo Y, Lei Y, Bai J, Cao L, Guo Z. Severe stomatitis caused by osimertinib combined with gefitinib: A case report. Clinical Case Reports 2022;10. [DOI: 10.1002/ccr3.5396] [Reference Citation Analysis]
295 Wu YL, Hirsh V, Sequist LV, Hu CP, Feng J, Lu S, Huang Y, Schuler M, Mok T, Yamamoto N, O'Byrne K, Geater SL, Zhou C, Massey D, Märten A, Lungershausen J, Yang JC. Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6). Patient 2018;11:131-41. [PMID: 29178024 DOI: 10.1007/s40271-017-0287-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
296 Tamiya M, Kunimasa K, Nishino K, Matsumoto S, Kawachi H, Kuno K, Inoue T, Kuhara H, Imamura F, Goto K, Kumagai T. Successful treatment of an osimertinib-resistant lung adenocarcinoma with an exon 18 EGFR mutation (G719S) with afatinib plus bevacizumab. Invest New Drugs 2021;39:232-6. [PMID: 32556898 DOI: 10.1007/s10637-020-00966-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
297 Boosman RJ, Burgers JA, Smit EF, Steeghs N, van der Wekken AJ, Beijnen JH, Huitema ADR, Ter Heine R. Optimized Dosing: The Next Step in Precision Medicine in Non-Small-Cell Lung Cancer. Drugs 2021. [PMID: 34894338 DOI: 10.1007/s40265-021-01654-3] [Reference Citation Analysis]
298 Hopkins AM, Shahnam A, Zhang S, Karapetis CS, Rowland A, Sorich MJ. Prognostic model of survival outcomes in non-small cell lung cancer patients initiated on afatinib: pooled analysis of clinical trial data. Cancer Biol Med 2019;16:341-9. [PMID: 31516754 DOI: 10.20892/j.issn.2095-3941.2018.0474] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
299 Moiseenko F, Volkov N, Zhabina A, Stepanova M, Rysev N, Klimenko V, Myslik A, Artemieva E, Egorenkov V, Abduloeva N, Ivantsov A, Kuligina E, Imyanitov E, Moiseyenko V. Monitoring of the presence of EGFR-mutated DNA during EGFR-targeted therapy may assist in the prediction of treatment outcome. Cancer Treatment and Research Communications 2022;31:100524. [DOI: 10.1016/j.ctarc.2022.100524] [Reference Citation Analysis]
300 Köhler J. Second-Line Treatment of NSCLC-The Pan-ErbB Inhibitor Afatinib in Times of Shifting Paradigms. Front Med (Lausanne) 2017;4:9. [PMID: 28243590 DOI: 10.3389/fmed.2017.00009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
301 Dagogo-Jack I, Azzolli CG, Fintelmann F, Mino-Kenudson M, Farago AF, Gainor JF, Jiang G, Piotrowska Z, Heist RS, Lennes IT, Temel JS, Mooradian MJ, Lin JJ, Digumarthy SR, Batten JM, Robinson H, Nose V, Rivera M, Nardi V, Dias-Santagata D, Le LP, Sequist LV, Pitman M, Shepard JO, Shaw AT, Iafrate AJ, Lennerz JK. Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer. JCO Precis Oncol 2018;2018. [PMID: 30370396 DOI: 10.1200/PO.17.00299] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
302 Santaniello A, Napolitano F, Servetto A, De Placido P, Silvestris N, Bianco C, Formisano L, Bianco R. Tumour Microenvironment and Immune Evasion in EGFR Addicted NSCLC: Hurdles and Possibilities. Cancers (Basel) 2019;11:E1419. [PMID: 31554160 DOI: 10.3390/cancers11101419] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
303 Xu ZY, Li JL. Comparative review of drug-drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer. Onco Targets Ther 2019;12:5467-84. [PMID: 31371986 DOI: 10.2147/OTT.S194870] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
304 Zhang H, Chen J, Liu T, Dang J, Li G. First-line treatments in EGFR-mutated advanced non-small cell lung cancer: A network meta-analysis. PLoS One 2019;14:e0223530. [PMID: 31581247 DOI: 10.1371/journal.pone.0223530] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
305 Zhang L, Luo Y, Chen J, Cheng T, Yang H, Pan C, Li H, Jiang Z. Efficacy and Safety of Afatinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with EGFR Mutations: A Meta-Analysis of Real-World Evidence. J Oncol 2021;2021:8736288. [PMID: 34961817 DOI: 10.1155/2021/8736288] [Reference Citation Analysis]
306 Koopman B, Cajiao Garcia BN, Kuijpers CCHJ, Damhuis RAM, van der Wekken AJ, Groen HJM, Schuuring E, Willems SM, van Kempen LC. A Nationwide Study on the Impact of Routine Testing for EGFR Mutations in Advanced NSCLC Reveals Distinct Survival Patterns Based on EGFR Mutation Subclasses. Cancers (Basel) 2021;13:3641. [PMID: 34298851 DOI: 10.3390/cancers13143641] [Reference Citation Analysis]
307 Yamamoto N, Mera T, Märten A, Hochmair MJ. Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib. Adv Ther 2020;37:759-69. [PMID: 31863283 DOI: 10.1007/s12325-019-01187-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
308 Wee P, Wang Z. Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. Cancers 2017;9:52. [DOI: 10.3390/cancers9050052] [78495111110.3390/cancers9050052','', '2307-8960')">Reference Citation Analysis]
309 Costa DB. Kinase inhibitor-responsive genotypes in EGFR mutated lung adenocarcinomas: moving past common point mutations or indels into uncommon kinase domain duplications and rearrangements. Transl Lung Cancer Res 2016;5:331-7. [PMID: 27413714 DOI: 10.21037/tlcr.2016.06.04] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
310 Barnes TA, O'Kane GM, Vincent MD, Leighl NB. Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer. Front Oncol 2017;7:113. [PMID: 28620581 DOI: 10.3389/fonc.2017.00113] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 6.2] [Reference Citation Analysis]
311 Azam F, Vazquez A. Trends in Phase II Trials for Cancer Therapies. Cancers (Basel) 2021;13:E178. [PMID: 33430223 DOI: 10.3390/cancers13020178] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
312 Kelly WJ, Shah NJ, Subramaniam DS. Management of Brain Metastases in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer. Front Oncol 2018;8:208. [PMID: 30018881 DOI: 10.3389/fonc.2018.00208] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 7.5] [Reference Citation Analysis]
313 Wang Z, Du X, Chen K, Li S, Yu Z, Wu Z, Yang L, Chen D, Liu W. Impact of Dose Reduction of Afatinib Used in Patients With Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Front Pharmacol 2021;12:781084. [PMID: 34912228 DOI: 10.3389/fphar.2021.781084] [Reference Citation Analysis]
314 Morabito A, Manzo A, Montanino A, Rachiglio AM, Sforza V, Pasquale R, Costanzo R, Maiello MR, Sandomenico C, Gallo M, Palumbo G, De Luca A, La rocca A, Martucci N, De Cecio R, Picone C, Lastoria S, Normanno N. Liquid Biopsy Testing for the Management of Patient with Non-Small Cell Lung Cancer Carrying a Rare Exon-20 EGFR Insertion. The Oncologist 2022. [DOI: 10.1093/oncolo/oyab002] [Reference Citation Analysis]
315 Bhateja P, Sharma N. Afatinib plus chemotherapy versus chemotherapy alone after progression on afatinib: new insights on old question? Ann Transl Med 2016;4:S31. [PMID: 27867999 DOI: 10.21037/atm.2016.09.45] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
316 Xing P, Zheng X, Wang Y, Chu T, Wang S, Jiang J, Qian J, Han X, Ding L, Wang Y, Cui L, Li H, Li L, Chen X, Han B, Hu P, Shi Y. Safety, pharmacokinetics, and efficacy of BPI-15086 in patients with EGFR T790M-mutated advanced non-small-cell lung cancer: results from a phase I, single-arm, multicenter study. ESMO Open 2022;7:100473. [DOI: 10.1016/j.esmoop.2022.100473] [Reference Citation Analysis]
317 Ameku K, Higa M. Complete Remission of Multiple Brain Metastases in a Patient with EGFR-Mutated Non-Small-Cell Lung Cancer Treated with First-Line Osimertinib without Radiotherapy. Case Rep Oncol Med 2020;2020:9076168. [PMID: 32257480 DOI: 10.1155/2020/9076168] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
318 Holleman MS, van Tinteren H, Groen HJ, Al MJ, Uyl-de Groot CA. First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis. Onco Targets Ther 2019;12:1413-21. [PMID: 30863108 DOI: 10.2147/OTT.S189438] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 7.3] [Reference Citation Analysis]
319 Xia W, Mao W, Chen R, Lu R, Liu F, He Y, Wang S, Li X, Zheng M. Epidermal Growth Factor Receptor Mutations in Resectable Non-Small Cell Lung Cancer Patients and their Potential Role in the Immune Landscape. Med Sci Monit 2019;25:8764-76. [PMID: 31746315 DOI: 10.12659/MSM.920042] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
320 Su VY, Yang KY, Huang TY, Hsu CC, Chen YM, Yen JC, Chou YC, Chang YL, He CH. The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancer. Sci Rep 2020;10:14965. [PMID: 32917914 DOI: 10.1038/s41598-020-71583-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
321 Liu Y, Jiang H, Zhou H, Ying X, Wang Z, Yang Y, Xu W, He X, Li Y. Lentivirus-mediated silencing of HOTAIR lncRNA restores gefitinib sensitivity by activating Bax/Caspase-3 and suppressing TGF-α/EGFR signaling in lung adenocarcinoma. Oncol Lett 2018;15:2829-38. [PMID: 29467862 DOI: 10.3892/ol.2017.7656] [Cited by in Crossref: 3] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
322 Chen F, Chen N, Yu Y, Cui J. Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus Antiangiogenic Agents as First-Line Treatments for Patients With Advanced EGFR-Mutated Non-small Cell Lung Cancer: A Meta-Analysis. Front Oncol 2020;10:904. [PMID: 32714857 DOI: 10.3389/fonc.2020.00904] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
323 Yamanaka Y, Seki Y, Ishikawa T, Kuwano K. Long-lasting response to afatinib that persisted after treatment discontinuation in a case of EGFR-mutated lung adenocarcinoma. BMJ Case Rep 2019;12:e227383. [PMID: 30709831 DOI: 10.1136/bcr-2018-227383] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
324 Liang SK, Hsieh MS, Lee MR, Keng LT, Ko JC, Shih JY. Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma. Oncotarget 2017;8:90430-43. [PMID: 29163842 DOI: 10.18632/oncotarget.19563] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 7.4] [Reference Citation Analysis]
325 Zhou Tran Y, Minozada R, Cao X, Johansson HJ, Branca RM, Seashore-Ludlow B, Orre LM. Immediate Adaptation Analysis Implicates BCL6 as an EGFR-TKI Combination Therapy Target in NSCLC. Mol Cell Proteomics 2020;19:928-43. [PMID: 32234966 DOI: 10.1074/mcp.RA120.002036] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
326 Jobe AL, Ahonen KT, Poplin V, Rao S, Mohyuddin GR. Afatinib-induced Interstitial Lung Disease Successfully Treated with Corticosteroids: Case Report and Review of the Literature. Cureus 2018;10:e2805. [PMID: 30123727 DOI: 10.7759/cureus.2805] [Reference Citation Analysis]
327 Saran F, Welsh L, James A, McBain C, Gattamaneni R, Jefferies S, Harris F, Pemberton K, Schaible J, Bender S, Cseh A, Brada M. Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial. J Neurooncol 2021;155:307-17. [PMID: 34787778 DOI: 10.1007/s11060-021-03877-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
328 Abughanimeh O, Kaur A, Osta BE, Ganti AK. Novel targeted therapies for advanced non-small lung cancer. Seminars in Oncology 2022. [DOI: 10.1053/j.seminoncol.2022.03.003] [Reference Citation Analysis]
329 Ninomiya K, Ohashi K, Makimoto G, Tomida S, Higo H, Kayatani H, Ninomiya T, Kubo T, Ichihara E, Hotta K, Tabata M, Maeda Y, Kiura K. MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib. Sci Rep 2018;8:1955. [PMID: 29386539 DOI: 10.1038/s41598-018-20326-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
330 Dantoing E, Piton N, Salaün M, Thiberville L, Guisier F. Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations. Int J Mol Sci 2021;22:6288. [PMID: 34208111 DOI: 10.3390/ijms22126288] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
331 Sekine A, Satoh H. Paradigm shift of therapeutic management of brain metastases in EGFR-mutant non-small cell lung cancer in the era of targeted therapy. Med Oncol 2017;34:121. [PMID: 28555261 DOI: 10.1007/s12032-017-0978-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
332 Brückl WM, Reck M, Griesinger F, Schäfer H, Kortsik C, Gaska T, Rawluk J, Krüger S, Kokowski K, Budweiser S, Ficker JH, Hoffmann C, Schüler A, Laack E. Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice. Ther Adv Med Oncol 2021;13:17588359211012361. [PMID: 33995597 DOI: 10.1177/17588359211012361] [Reference Citation Analysis]
333 Decoster L, Giron P, Mignon S, De Grève J. The evolving first-line treatment of advanced non-small cell lung cancer harbouring epidermal growth factor receptor mutations. Transl Lung Cancer Res 2018;7:S134-7. [PMID: 29780706 DOI: 10.21037/tlcr.2018.03.08] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
334 Yang CJ, Tsai MJ, Hung JY, Lee MH, Tsai YM, Tsai YC, Hsu JF, Liu TC, Huang MS, Chong IW. The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations. BMC Pharmacol Toxicol 2017;18:82. [PMID: 29237484 DOI: 10.1186/s40360-017-0190-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
335 Wang Y, Zheng D, Luo J, Zhang J, Pompili C, Ujiie H, Matsuura N, Chen H, Yao F. Risk stratification model for patients with stage I invasive lung adenocarcinoma based on clinical and pathological predictors. Transl Lung Cancer Res 2021;10:2205-17. [PMID: 34164270 DOI: 10.21037/tlcr-21-393] [Reference Citation Analysis]
336 Mu Y, Hao X, Yang K, Ma D, Wang S, Xu Z, Li J, Xing P. Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib. Target Oncol 2019;14:335-42. [PMID: 31124059 DOI: 10.1007/s11523-019-00644-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
337 Testa U, Castelli G, Pelosi E. Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells. Cancers (Basel) 2018;10:E248. [PMID: 30060526 DOI: 10.3390/cancers10080248] [Cited by in Crossref: 97] [Cited by in F6Publishing: 108] [Article Influence: 24.3] [Reference Citation Analysis]
338 Logan JM, Brooks DA, Rowland A, Sorich MJ, Hopkins AM. Survival Outcomes of Nonsmall Cell Lung Cancer Patients Treated with Afatinib Who Are Affected by Early Adverse Events. J Oncol 2021;2021:2414897. [PMID: 34221011 DOI: 10.1155/2021/2414897] [Reference Citation Analysis]
339 Lasala R, Santoleri F, Romagnoli A, Musicco F, Costantini A. Dosage adjustments in pivotal clinical trials with oral targeted therapies in solid tumors conducted in Europe. Eur J Clin Pharmacol 2019;75:697-706. [PMID: 30617511 DOI: 10.1007/s00228-018-02621-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
340 Xu X, Fang N, Li H, Liu Y, Yang F, Li X. Cost-effectiveness analysis of dacomitinib versus gefitinib for the first-line therapy of patients with EGFR mutation-positive non-small-cell lung cancer in the United States and China. Ann Transl Med 2021;9:760. [PMID: 34268373 DOI: 10.21037/atm-20-6992] [Reference Citation Analysis]
341 Amelia T, Kartasasmita RE, Ohwada T, Tjahjono DH. Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors. Molecules 2022;27:819. [PMID: 35164092 DOI: 10.3390/molecules27030819] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
342 Brouns A, Dursun S, Bootsma G, Dingemans AC, Hendriks L. Reporting of Incidence and Outcome of Bone Metastases in Clinical Trials Enrolling Patients with Epidermal Growth Factor Receptor Mutated Lung Adenocarcinoma-A Systematic Review. Cancers (Basel) 2021;13:3144. [PMID: 34201833 DOI: 10.3390/cancers13133144] [Reference Citation Analysis]
343 Yamamoto Y, Kodama K, Maniwa T, Takeda M. Surgical resection of advanced non-small cell lung cancer after a response to EGFR-TKI: presentation of two cases and a literature review. J Cardiothorac Surg 2017;12:98. [PMID: 29169381 DOI: 10.1186/s13019-017-0668-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
344 Kitadai R, Okuma Y. Treatment Strategies for Non-Small Cell Lung Cancer Harboring Common and Uncommon EGFR Mutations: Drug Sensitivity Based on Exon Classification, and Structure-Function Analysis. Cancers 2022;14:2519. [DOI: 10.3390/cancers14102519] [Reference Citation Analysis]
345 Popescu C, Mazilu L, Suceveanu AI, Grigorescu A. How specific molecular-targeted agents can make obsolete a 'one size fits all' approach in EGFR-mutated NSCLC treatment (Review). Exp Ther Med 2021;22:1150. [PMID: 34504595 DOI: 10.3892/etm.2021.10584] [Reference Citation Analysis]
346 Keppens C, Dequeker EMC, Rouleau E, 't Hart N, Bubendorf L, Dufraing K, Garrec C, Guéguen P, Lamy A, Marchetti A, Pauwels P, Ryska A, Tack V, Tornillo L, Van Casteren K, von der Thüsen JH, Zwaenepoel K, Lissenberg-Witte B, Thunnissen E, Schuuring E. Sensitive detection methods are key to identify secondary EGFR c.2369C>T p.(Thr790Met) in non-small cell lung cancer tissue samples. BMC Cancer 2020;20:366. [PMID: 32357863 DOI: 10.1186/s12885-020-06831-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
347 Okuma Y, Hosomi Y. Osimertinib for advanced non-small cell lung cancer harboring EGFR mutation exon 20 T790M, acquired resistant mutation for first- or second-generation EGFR-TKI. J Thorac Dis 2017;9:470-3. [PMID: 28449447 DOI: 10.21037/jtd.2017.03.26] [Reference Citation Analysis]
348 Liang S, Xu Y, Tan F, Ding L, Ma Y, Wang M. Efficacy of icotinib in advanced lung squamous cell carcinoma. Cancer Med 2018;7:4456-66. [PMID: 30109777 DOI: 10.1002/cam4.1736] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
349 Makimoto G, Nishi T, Kawakado K, Nishimura T, Tamura T, Kudo K, Kuyama S. Successful Desensitization Treatment with Osimertinib after the Development of Osimertinib-induced Urticaria in a Patient Undergoing Treatment for Non-small Cell Lung Cancer Harboring the EGFR T790M Mutation. Intern Med 2020;59:2161-4. [PMID: 32461525 DOI: 10.2169/internalmedicine.4429-20] [Reference Citation Analysis]
350 Yamaura T, Ezaki J, Okabe N, Takagi H, Ozaki Y, Inoue T, Watanabe Y, Fukuhara M, Muto S, Matsumura Y, Hasegawa T, Hoshino M, Osugi J, Shio Y, Waguri S, Tamura H, Imai JI, Ito E, Yanagisawa Y, Honma R, Watanabe S, Suzuki H. Family with sequence similarity 83, member B is a predictor of poor prognosis and a potential therapeutic target for lung adenocarcinoma expressing wild-type epidermal growth factor receptor. Oncol Lett 2018;15:1549-58. [PMID: 29434849 DOI: 10.3892/ol.2017.7517] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
351 Xu Y, Ding VW, Zhang H, Zhang X, Jablons D, He B. Spotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so far. Ther Clin Risk Manag 2016;12:807-16. [PMID: 27307741 DOI: 10.2147/TCRM.S92996] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
352 Zhang T, Joubert P, Ansari-Pour N, Zhao W, Hoang PH, Lokanga R, Moye AL, Rosenbaum J, Gonzalez-Perez A, Martínez-Jiménez F, Castro A, Muscarella LA, Hofman P, Consonni D, Pesatori AC, Kebede M, Li M, Gould Rothberg BE, Peneva I, Schabath MB, Poeta ML, Costantini M, Hirsch D, Heselmeyer-Haddad K, Hutchinson A, Olanich M, Lawrence SM, Lenz P, Duggan M, Bhawsar PMS, Sang J, Kim J, Mendoza L, Saini N, Klimczak LJ, Islam SMA, Otlu B, Khandekar A, Cole N, Stewart DR, Choi J, Brown KM, Caporaso NE, Wilson SH, Pommier Y, Lan Q, Rothman N, Almeida JS, Carter H, Ried T, Kim CF, Lopez-Bigas N, Garcia-Closas M, Shi J, Bossé Y, Zhu B, Gordenin DA, Alexandrov LB, Chanock SJ, Wedge DC, Landi MT. Genomic and evolutionary classification of lung cancer in never smokers. Nat Genet 2021;53:1348-59. [PMID: 34493867 DOI: 10.1038/s41588-021-00920-0] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
353 Han L, Zhang X, Wang Z, Zhang X, Zhao L, Fu W, Liang X, Zhang Z, Wang Y. SH-1028, An Irreversible Third-Generation EGFR TKI, Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer. Front Pharmacol 2021;12:665253. [PMID: 33986687 DOI: 10.3389/fphar.2021.665253] [Reference Citation Analysis]
354 Tamiya M, Fujikawa K, Suzuki H, Yokoyama T, Uenami T, Tamiya A, Sato Y, Saito G, Uchida J, Morita M, Hirashima T, Fukuda Y, Kanazu M, Hosoya K, Suzuki T, Ueno K, Fujimoto D, Kumagai T, Teramukai S. Classification and regression tree for estimating predictive markers to detect T790M mutations after acquired resistance to first line EGFR-TKI: HOPE-002. Invest New Drugs 2022. [PMID: 35088212 DOI: 10.1007/s10637-021-01203-5] [Reference Citation Analysis]
355 Tu HY, Feng J, Shi M, Zhao J, Wang Y, Chang J, Wang J, Cheng Y, Zhu J, Tan EH, Li K, Zhang Y, Lee V, Yang CT, Su WC, Lam DC, Srinivasa BJ, Rajappa S, Ho CL, Lam KC, Hu Y, Bondarde SA, Liu X, Tian Y, Xue Z, Cseh A, Huang DC, Zhou C, Wu YL. A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China. Target Oncol 2022. [PMID: 35020119 DOI: 10.1007/s11523-021-00859-6] [Reference Citation Analysis]
356 Yi L, Fan J, Qian R, Luo P, Zhang J. Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: A meta-analysis. Int J Cancer 2019;145:284-94. [PMID: 30613959 DOI: 10.1002/ijc.32097] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
357 Hsu PC, Huang CY, Wang CC, Kuo SC, Chu CH, Tung PH, Huang AC, Wang CL, Chiu LC, Fang YF, Yang CT. The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study. Pharmaceuticals (Basel) 2020;13:E331. [PMID: 33113888 DOI: 10.3390/ph13110331] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
358 Xu J, Wang J, Zhang S. Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer. Oncotarget 2017;8:90557-78. [PMID: 29163853 DOI: 10.18632/oncotarget.21164] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
359 Wei J, Yin Y, Zhou J, Chen H, Peng J, Yang J, Tang Y. METTL3 potentiates resistance to cisplatin through m6 A modification of TFAP2C in seminoma. J Cell Mol Med 2020;24:11366-80. [PMID: 32857912 DOI: 10.1111/jcmm.15738] [Cited by in Crossref: 7] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
360 Park K, Tan DSW, Su WC, Cho BC, Kim SW, Lee KH, Wang CC, Seto T, Huang DC, Jung HH, Hsu MC, Bogenrieder T, Lin CC. Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors. JTO Clin Res Rep 2021;2:100206. [PMID: 34590052 DOI: 10.1016/j.jtocrr.2021.100206] [Reference Citation Analysis]
361 Ohmori T, Yamaoka T, Ando K, Kusumoto S, Kishino Y, Manabe R, Sagara H. Molecular and Clinical Features of EGFR-TKI-Associated Lung Injury. Int J Mol Sci 2021;22:E792. [PMID: 33466795 DOI: 10.3390/ijms22020792] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
362 Agulnik JS, Kasymjanova G, Pepe C, Hurry M, Walton RN, Sakr L, Cohen V, Small D. Real-World Pattern of Treatment and Clinical Outcomes of EGFR-Mutant Non-Small Cell Lung Cancer in a Single Academic Centre in Quebec. Curr Oncol 2021;28:5179-91. [PMID: 34940073 DOI: 10.3390/curroncol28060434] [Reference Citation Analysis]
363 Zheng Y, Zhou M, Arulananda S, Um SW, Li H. Management of non-small cell lung cancer with resistance to epidermal growth factor receptor tyrosine kinase inhibitor: case discussion. J Thorac Dis 2020;12:159-64. [PMID: 32274080 DOI: 10.21037/jtd.2020.01.65] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
364 Vavalà T. Role of afatinib in the treatment of advanced lung squamous cell carcinoma. Clin Pharmacol 2017;9:147-57. [PMID: 29225480 DOI: 10.2147/CPAA.S112715] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
365 Cheng Y, Zhang T, Xu Q. Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy. MedComm (2020) 2021;2:692-729. [PMID: 34977873 DOI: 10.1002/mco2.105] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
366 Houron C, Danielou M, Mir O, Fromenty B, Perlemuter G, Voican CS. Multikinase inhibitor-induced liver injury in patients with cancer: A review for clinicians. Crit Rev Oncol Hematol 2021;157:103127. [PMID: 33161366 DOI: 10.1016/j.critrevonc.2020.103127] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
367 Minegishi Y, Yamaguchi O, Sugawara S, Kuyama S, Watanabe S, Usui K, Mori M, Hataji O, Nukiwa T, Morita S, Kobayashi K, Gemma A. A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027. BMC Cancer 2021;21:208. [PMID: 33648453 DOI: 10.1186/s12885-021-07861-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
368 Watanabe S, Hayashi H, Nakagawa K. Is afatinib a treatment option for brain metastases in patients with EGFR mutation-positive non-small cell lung cancer? Ann Transl Med 2016;4:225. [PMID: 27385269 DOI: 10.21037/atm.2016.05.48] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
369 Xu Z, Li J. [Review on the Combination Strategy of Anti-angiogenic Agents 
and Other Anti-tumor Agents in Advanced Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2021;24:357-64. [PMID: 34034460 DOI: 10.3779/j.issn.1009-3419.2021.101.16] [Reference Citation Analysis]
370 Park K, Kim JS, Kim JH, Kim YC, Kim HG, Cho EK, Jin JY, Kim M, Märten A, Kang JH. An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations. BMC Cancer 2021;21:802. [PMID: 34253172 DOI: 10.1186/s12885-021-08445-9] [Reference Citation Analysis]
371 Peters M, Kim ES, Hirsch V. Clinical Use of Epidermal Growth Factor Receptor Testing in Patients With Advanced Lung Cancer by Physicians: Survey of US and International Patterns. J Glob Oncol 2019;5:1-7. [PMID: 30811306 DOI: 10.1200/JGO.18.00057] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
372 Ricciuti B, Baglivo S, De Giglio A, Chiari R. Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience. Ther Adv Respir Dis 2018;12:1753466618808659. [PMID: 30355049 DOI: 10.1177/1753466618808659] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
373 Del Re M, Cucchiara F, Petrini I, Fogli S, Passaro A, Crucitta S, Attili I, De Marinis F, Chella A, Danesi R. erbB in NSCLC as a molecular target: current evidences and future directions. ESMO Open 2020;5:e000724. [PMID: 32820012 DOI: 10.1136/esmoopen-2020-000724] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
374 Hochmair M. Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and/or Leptomeningeal Disease. Target Oncol 2018;13:269-85. [PMID: 29700687 DOI: 10.1007/s11523-018-0566-1] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 10.7] [Reference Citation Analysis]
375 Tu HY, Wu YL. Effect of Dose Adjustments on the Safety and Efficacy of Afatinib in Chinese Patients with EGFR-Mutated Non-Small Cell Lung Cancer Who Participated in the LUX-Lung Clinical Trial Program. Onco Targets Ther 2020;13:12539-47. [PMID: 33324072 DOI: 10.2147/OTT.S273866] [Reference Citation Analysis]
376 Huang YH, Tseng JS, Hsu KH, Chen KC, Su KY, Yu SL, Chen JJW, Yang TY, Chang GC. The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M. Sci Rep 2021;11:12084. [PMID: 34103652 DOI: 10.1038/s41598-021-91657-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
377 Chiu TH, Lin CY, Hsieh MH, Lin SM, Fang YF. Prognostic Factors in Lung Adenocarcinoma with Bone Metastasis Treated with EGFR-TKIs. Medicina (Kaunas) 2021;57:967. [PMID: 34577890 DOI: 10.3390/medicina57090967] [Reference Citation Analysis]
378 Pi C, Xu CR, Zhang MF, Peng XX, Wei XW, Gao X, Yan HH, Zhou Q. EGFR mutations in early-stage and advanced-stage lung adenocarcinoma: Analysis based on large-scale data from China. Thorac Cancer 2018;9:814-9. [PMID: 29722148 DOI: 10.1111/1759-7714.12651] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
379 Kim M, Baek M, Kim DJ. Protein Tyrosine Signaling and its Potential Therapeutic Implications in Carcinogenesis. Curr Pharm Des 2017;23:4226-46. [PMID: 28625132 DOI: 10.2174/1381612823666170616082125] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
380 Lee IH, Yang CY, Shih JY, Yu CJ. Tyrosine Kinase Inhibitors Improved Survival of Critically Ill EGFR-Mutant Lung Cancer Patients Undergoing Mechanical Ventilation. Biomedicines 2021;9:1416. [PMID: 34680533 DOI: 10.3390/biomedicines9101416] [Reference Citation Analysis]
381 Westover D, Zugazagoitia J, Cho BC, Lovly CM, Paz-Ares L. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol. 2018;29:i10-i19. [PMID: 29462254 DOI: 10.1093/annonc/mdx703] [Cited by in Crossref: 157] [Cited by in F6Publishing: 160] [Article Influence: 52.3] [Reference Citation Analysis]
382 Bozorgmehr F, Kazdal D, Chung I, Kirchner M, Magios N, Kriegsmann M, Allgäuer M, Klotz LV, Muley T, El Shafie RA, Fischer JR, Faehling M, Stenzinger A, Thomas M, Christopoulos P. De Novo Versus Secondary Metastatic EGFR-Mutated Non-Small-Cell Lung Cancer. Front Oncol 2021;11:640048. [PMID: 33898315 DOI: 10.3389/fonc.2021.640048] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
383 Lin JZ, Ma SK, Wu SX, Yu SH, Li XY. A network meta-analysis of nonsmall-cell lung cancer patients with an activating EGFR mutation: Should osimertinib be the first-line treatment? Medicine (Baltimore) 2018;97:e11569. [PMID: 30045282 DOI: 10.1097/MD.0000000000011569] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
384 Brat K, Bratova M, Skrickova J, Barinova M, Hurdalkova K, Pesek M, Havel L, Koubkova L, Hrnciarik M, Krejci J, Fischer O, Zemanova M, Coupkova H, Svaton M. Real-life effectiveness of first-line anticancer treatments in stage IIIB/IV NSCLC patients: Data from the Czech TULUNG Registry. Thorac Cancer 2020;11:3346-56. [PMID: 33016001 DOI: 10.1111/1759-7714.13679] [Reference Citation Analysis]
385 Osborn LP, Cohen PR. Afatinib-Associated Cutaneous Toxicity: A Correlation of Severe Skin Reaction with Dramatic Tumor Response in a Woman with Exon 19 Deletion Positive Non-Small-Cell Lung Cancer. Cureus 2016;8:e763. [PMID: 27725919 DOI: 10.7759/cureus.763] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
386 Chang CY, Lai YC, Wei YF, Chen CY, Chang SC. PD-L1 Expression and Outcome in Patients with Metastatic Non-Small Cell Lung Cancer and EGFR Mutations Receiving EGFR-TKI as Frontline Treatment. Onco Targets Ther 2021;14:2301-9. [PMID: 33833528 DOI: 10.2147/OTT.S290445] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
387 Mountzios G, Lampaki S, Koliou GA, Vozikis A, Kontogiorgos I, Papantoniou P, Koufaki MI, Res E, Boutis A, Christopoulou A, Pastelli N, Grivas A, Aravantinos G, Lalla E, Oikonomopoulos G, Koumarianou A, Spyratos D, Bafaloukos D, Rigakos G, Papakotoulas P, Fountzilas G, Linardou H. An Observational Study to Assess the Molecular Epidemiology and Direct Medical Costs of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer Treated with Afatinib in Real-World Clinical Settings in Greece. Lung Cancer (Auckl) 2021;12:93-102. [PMID: 34512058 DOI: 10.2147/LCTT.S318007] [Reference Citation Analysis]
388 Zhao Y, Liu J, Cai X, Pan Z, Liu J, Yin W, Chen H, Xie Z, Liang H, Wang W, Guo Z, Zhao S, Liang W, He J. Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis. BMJ 2019;367:l5460. [PMID: 31591158 DOI: 10.1136/bmj.l5460] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 11.0] [Reference Citation Analysis]